2016N275054_04 CONFIDENTIA L
The GlaxoSmithKline group of companies 204959
1TITLE PA GE
Division: World wide Development
Information Type: Protocol Amendment
Title: An open -label, single arm, repeat dose, multi -centre study  to 
evaluate the use of an autoinjector for the subcutaneous 
administration of mepolizumab in subjects with severe 
eosinophilic asthma (Study  204959)
Compound Number: SB-240563
Development Phase: III
Effective Date: 15-FEB-2017
Protocol Amendment Number:  02
Author (s):  
Copy right 2017 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised cop ying or use of this information is prohibited.
PPD
PPD
2016N275054_04 CONFIDENTIA L
The GlaxoSmithKline group of companies 204959
2Revision Chronology
GlaxoSmith Kline
Document NumberDate Version
2016N275054_00 2016 -AUG-12 Original
2016N275054_01 2016 -AUG-18 Republishing
To add serious s ystemic reactions including anaphy laxis to the risk assessment section. 
To remove GCSP as a contributory  author as per GUI_264305 (3.0).
To clarify  the wording around assessing eosinophilia from blood counts collected 
following a Liver Stopping Ev ent
2016N275054_02 2016 -OCT -06 Amendment No. 1
To refine the criteria for a successful injection following a use -related risk review
To amend Exclusion Criterion 7 to allow either Fridericia’s or Bazett’s to be used as the 
correction formula for heart rate when measuring the QT interval
To remove Exclusion Criterion 15 as the exclusion of pregnant or lactating females is 
covered in Inclusion Criterion 9
To correct minor typographical errors
2016N275054_03 2016 -OCT -13 Amendment No. 1 
(Republish)
To include Appendix 9 detailing the changes to the original protocol
2016N275054_04 2017 -FEB-15 Amendment No. 2
To include information regarding a change to the labelling of the autoinjector so that two 
different labelling formats will be used, depending on geographical region
To increase the subject numbers as a result of the introduction of two different label 
formats and to indicate that the results will be presented separatel y according to the label 
format
To amend inclusion criterion 5 to allow subjects to be enrolled who require high dose 
inhaled corticosteroids to prevent exacerbations but who may  not have received 
continuous high dose inhaled corticosteroids due to financial or tolerance issues
To remove ‘incidence of asthma exacerbations’ as safet y endpoint and reclassify  as an
other endpoint
To change the wording to indicate that all used autoinjectors should to be returned to 
GSK rather than just faulty  devices
To remove reference to a practice injection into a foam pad prior the first injection at
2016N275054_04 CONFIDENTIA L
The GlaxoSmithKline group of companies 204959
3Visit 2
To add the assessment of asthma exacerbations during the stud y to the Time and Events 
table and under Section 7.7.8
To correct minor typographical errors
PP
D
PPD
PPD
PP
D
2016N275054_0 4 CONFIDENTIA L
204959
5MEDICA L MONITOR/SPON SOR INFORM ATION PA GE
Medical Monitor/SAE Contact Information: 
Role Name Day Time Phone Number and 
email addressAfter -hours 
Phone/Cell/
Pager 
NumberFax 
NumberSite Address
Primary 
Medical 
Monitor Telephone: Cell: Fax: GlaxoSmithKline
Upper Merion
709 Swedeland 
Road, King of 
Prussia, PA –
19406
USA
Secondary 
Medical 
MonitorTelephone: Cell: Fax: GlaxoSmithKline
Upper Merion
709 Swedeland 
Road, King of 
Prussia, PA –
19406
USA
SAE 
contact  
information Telephone: Cell: Fax: GlaxoSmithKline
Upper Merion
709 Swedeland 
Road, King of 
Prussia, PA –
19406
USA
Sponsor Legal Registered Address: 
GlaxoSmithKline Research & Development Limited
980 Great West Road
Brentford
Middlesex, TW8 9GS
UK
In some countries, the clinical trial sponsor may  be the local GlaxoSmithKline Affiliate 
Company  (or designee). If applicable, the details of the alternative Sponsor and contact 
person in the territory  will be provided to the relevant regulatory  authority  as part of the 
clinical trial application.   
Regulatory  Agency  Identify ing Number(s): IND No 006971, EudraCT No: 2016-001832-
36
PPD
PPD
PPD
PPD
PPD
PP
D
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
2016N275054_0 4 CONFIDENTIA L
204959
6INVESTIGA TOR PROTOCOL AGREEMENT PA GE
For protocol number 204959
Iconfirm agreement to conduct the study  in compliance with the protocol, as amended by  
this protocol amendment.
I acknowledge that I am responsible for overall study  conduct. I agree to personall y 
conduct or super vise the described stud y.
I agree to ensure that all associates, colleagues and employ ees assisting in the conduct of 
the study  are informed about their obligations. Mechanisms are in place to ensure that site 
staff receives the appropriate information thr oughout the study . 
Investigator Name:
Investigator Address:
Investigator Phone Number:
Investigator Signature Date
2016N275054_0 4 CONFIDENTIA L
204959
7TABLE OF CONTENTS
PAGE
1.PROTOCOL SYNOPSIS FO R STUDY 204959 ...................................................... 10
2.INTRODUCTION .................................................................................................... 12
2.1. Study Rationale .......................................................................................... 12
2.2. Brief Background ........................................................................................ 13
3.OBJECTIVE(S) AND END POINT(S) ...................................................................... 14
4.STUDY DESIGN .................................................................................................... 16
4.1. Overall Design ............................................................................................ 16
4.2. Treatment Arms and Duration ..................................................................... 18
4.3. Type and Number of Subjects ..................................................................... 20
4.4. Design Justification ..................................................................................... 20
4.5. Dose Justification ........................................................................................ 21
4.6. Benefit:Risk Assessment ............................................................................ 21
4.6.1. Risk Assessment ......................................................................... 22
4.6.2. Benefit Assessment ..................................................................... 26
4.6.3. Overall Benefit:Risk Conclusion ................................................... 26
5.SELECTION OF STUDY P OPULATION AND WITHDR AWAL CRITERIA ............. 26
5.1. Inclusion Criteria ......................................................................................... 26
5.2. Exclusion Criteria ........................................................................................ 29
5.3. Continuation to Treatment Criteria .............................................................. 30
5.4. Pre-Screening/Screening Failures .............................................................. 31
5.5. Withdrawal/Stopping Criteria ....................................................................... 32
5.5.1. Withdrawal from the Study ........................................................... 32
5.5.2. Liver Chemistry Stopping Criteria ................................................ 33
5.5.2.1. Study Treatment Restart or Rechallenge .................... 34
5.5.3. QTc Stopping Criteria .................................................................. 34
5.6. Subject and Study Completion .................................................................... 35
6.STUDY TREATMENT ............................................................................................ 35
6.1. Investigational Product and Other Study Treatment .................................... 35
6.2. Medical Devices .......................................................................................... 36
6.3. Treatment Assignment ................................................................................ 37
6.4. Blinding ....................................................................................................... 37
6.5. Packaging and Labelling ............................................................................. 37
6.6. Preparation/Handling/Storage/Accountability .............................................. 37
6.7. Training Session ......................................................................................... 38
6.8. Compliance with Study Treatment Administration ....................................... 38
6.8.1. Self-Administration at the C linic................................................... 38
6.8.2. Self-Administration Outside the Clinic .......................................... 39
6.9. Treatment of Study Treatment Overdose .................................................... 39
6.10. Treatment after the End of the Study .......................................................... 39
6.11. Concomitant Medications and Non -Drug Therapies .................................... 40
6.11.1. Permitted Medications and Non -Drug Therapies .......................... 40
6.11.2. Prohibited Medications and Non -Drug Therapies ......................... 41
2016N275054_0 4 CONFIDENTIA L
204959
87.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 41
7.1. Time and Events Table ............................................................................... 42
7.2. Screening and Critical Baselin e Assessments ............................................ 45
7.2.1. Critical procedures performed at Screening (Visit 1) .................... 45
7.2.2. Critical procedures performed at first treatment Visit 
(Baseline Visit 2) .......................................................................... 46
7.3. Assessment of Autoinjector Use ................................................................ .46
7.4. Pain Assessment ........................................................................................ 47
7.5. Device Usability/Functionality Question ...................................................... 47
7.6. Exit Interviews ............................................................................................ 47
7.7. Safety ......................................................................................................... 48
7.7.1. Adverse Events (AE) and Serious Adverse Events (SAEs) .......... 48
7.7.1.1. Time period and Frequency for collecting AE 
and SAE information ................................................... 48
7.7.1.2. Method of Detecting AEs and SAEs ........................... 49
7.7.1.3. Follow -up of AEs and SAEs ........................................ 49
7.7.1.4. Cardiovascular and Death Events .............................. 49
7.7.1.4.1. Cardiovascular events ............................ 49
7.7.1.4.2. Deaths .................................................... 49
7.7.1.5. Regulatory Reporting Requirements for SAEs ............ 49
7.7.2. Pregnancy ................................................................................... 50
7.7.3. Medical Device Incidents (Including Malfunctions) ....................... 50
7.7.3.1. Time Period for Detecting Medical Device 
Incidents ..................................................................... 50
7.7.3.2. Follow -up of Medical Device Incidents ........................ 51
7.7.3.3. Prompt Reporting of Medical Device Incidents 
to GSK ........................................................................ 51
7.7.3.4. Regulatory Reporting Requirements for 
Medical Devi ce Incidents ............................................ 51
7.7.4. Physical Exams ........................................................................... 51
7.7.5. Vital Signs .................................................................................... 52
7.7.6. Electrocardiogram (ECG) ............................................................. 52
7.7.7. Clinical Safety Laboratory Assessments ...................................... 52
7.8. Asthma Exacerbations ................................................................................ 53
7.9. Pharmacodynamic Markers ........................................................................ 54
7.10. Pharmacokinetics ....................................................................................... 54
7.11. Immunogenicity ........................................................................................... 54
7.12. Genetics ..................................................................................................... 54
8.DATA MANAGEMENT ........................................................................................... 55
9.STATISTICAL CONSIDER ATIONS AND DATA ANALYSES ................................ .55
9.1. Hypotheses ................................................................................................ .55
9.2. Sample Size Considerations ....................................................................... 55
9.2.1. Sample Size Assumptions ........................................................... 55
9.2.2. Sample Size Sensitivity ................................................................ 56
9.3. Data Analysis Considerations ..................................................................... 56
9.3.1. Analysis Populations .................................................................... 56
9.3.2. Treatment Comparisons .............................................................. 57
9.3.3. Interim Analysis ........................................................................... 57
9.4. Key Elements of Analysis Plan ................................................................... 57
9.4.1. Analyses to Evaluate Autoinjector ................................................ 57
2016N275054_0 4 CONFIDENTIA L
204959
99.4.2. Safety Analyses ........................................................................... 58
9.4.3. Pharmacodynamic Analyses ........................................................ 58
9.4.4. Pharmacokinetic Analyses ........................................................... 58
10. STUDY GOVERNANCE CON SIDERATIONS ........................................................ 59
10.1. Posting of Information on Publicly Available Clinical Trial Registers ............ 59
10.2. Regulatory and Ethical Considerations, Including the Informed 
Consent Process ........................................................................................ 59
10.3. Quality Control (Study Monitoring) .............................................................. 60
10.4. Quality Assurance ....................................................................................... 60
10.5. Study and Site Closure ............................................................................... 60
10.6. Records Retention ...................................................................................... 61
10.7. Provision of Study Results to Investigators, Posting of Information 
on Publically Available Clinical Trials Registers and Publication ................. 61
11.REFERENCES ....................................................................................................... 63
12.APPENDICES ........................................................................................................ 64
12.1. Appendix 1: Abbreviations and Trademarks ................................................ 64
12.2. Appendix 2: Anaphylaxis Criteria ................................................................ 67
12.3. Appendix 3 : Modified List of Highly Effective Methods for Avoiding 
Pregnancy in FRP and Collection of Pregnancy Information ....................... 68
12.3.1. Definition of post menopausal female .......................................... 68
12.3.2. Modified List of Highly Effective Methods for Avoiding 
Pregnancy in Females of Reproductive Potential (FRP) .............. 68
12.3.3. Collection of Pregnancy Information ............................................ 69
12.3.4. References .................................................................................. 70
12.4. Appendix 4: Liver Safety Required Actions and Follow up 
Assessments .............................................................................................. 71
12.4.1. Liver chemistry stopping criteria and required follow up 
assessments ................................................................................ 71
12.4.2. Liver chemistry increased monitoring criteria with 
continued therapy ........................................................................ 73
12.5. Appendix 5: Definition of and Procedures for Documenting Medical 
Device Incidents ......................................................................................... 74
12.5.1. Definitions of a Medical Device Incident ....................................... 74
12.5.2. Documenting Medical Device Incidents ....................................... 75
12.6. Appendix 6: Definition of and Procedures for Recording, Evaluating, 
Follow -Up and Reporting of Adverse Events ............................................... 76
12.6.1. Definition of Adverse Events ........................................................ 76
12.6.2. Definition of Serious Adverse Events ........................................... 77
12.6.3. Definition of Cardiovascular Events ............................................. 78
12.6.4. Recording of AEs and SAEs ........................................................ 79
12.6.5. Evaluating AEs and SAEs ............................................................ 79
12.6.6. Reporting of SAEs to GSK ........................................................... 81
12.7. Appendix 7: Genetic Research ................................................................... 82
12.8. Appendix 8 -Country Specific Requirements .............................................. 85
12.9. Appendix 9: Protocol Changes .................................................................... 86
12.9.1. Protocol Amendment 02 .............................................................. 86
12.9.2. Protocol Amendment 01 .............................................................. 99
2016N275054_0 4 CONFIDENTIA L
204959
101. PROTOCOL SYNOPSIS FOR STUDY 204959
Rationale
Mepolizumab (SB -240563) is a humanised monoclonal antibody  (IgG1, kappa, mAb) 
that blocks human interleukin -5 (hIL -5) from binding to the IL -5 receptor complex 
expressed on the eosinophil cell surface and thus inhibits signalling; neutralisation of IL -
5 with mepolizumab reduces blood, sputum and tissue eosinophils.
Mepolizumab for Injection is supplied as a sterile, s ingle -use, preservative -free, 
lyophilised powder formulation (herein referred to as ly ophilised drug product). This is 
the form that was used in the clinical development programmes and is the current 
marketed presentation for asthma (NUCALATM). Before use, a healthcare provider must 
reconstitute each vial of ly ophilised drug product with water for injection using aseptic 
techniques. As part of the life -cycle of mepolizumab, a liquid drug product provided as a 
ready-to-use pre -filled s yringe assembled into e ither a safet y syringe or an autoinjector, 
Mepolizumab I njection, has been developed.  Administration of Mepolizumab I njection 
(herein referred to as liquid drug product in autoinjector) will improve patient/phy sician 
convenience and enable home/self injec tion via caregivers and/or patients.
Objective(s)/Endpoint(s)
The aim of this study  is to assess the correct real -world use of an autoinjector for the 
repeat self -administration of mepolizumab subcutaneously  by determining the proportion 
of subjects with severe eosinophilic asthma who are successfull y able to self -administer a 
dose of mepolizumab. For the purposes of this study , ‘self -administration’ is defined as 
either the administration of mepolizumab liquid drug product in autoinjector by  the 
subject t hemselves or b y their caregiver.
The primary  and secondary  objectives and associated endpoints are outlined below:
Objectives Endpoints
Primary
To assess the use of the combination 
product, mepolizumab liquid drug 
product in autoinjector for the 
subcutaneous self -administration of 
mepolizumab by  subjects with severe 
eosinophilic asthmaProportion of subjects successfull y able 
to self -administer their observed third 
dose at Week 8
Secondary
To assess the use of mepolizumab 
liquid drug product in autoinjector 
outside the clinic settingProportion of subjects successfull y 
able to self -administer their 
unobserved second dose outside the 
clinic setting at Week 4
2016N275054_0 4 CONFIDENTIA L
204959
11Overall Design
This Phase III stud y will be an open- label, single -arm, repeat -dose, mul ti-centre study  of 
mepolizumab liquid drug product in autoinjector (100 mg) administered subcutaneousl y 
(SC) every  4 weeks in subjects with severe eosinophilic asthma.  Subjects will receive 
100 mg mepolizumab SC as a single injection that is self -administ ered in the thigh, 
abdomen or administered in the upper arm (caregiver only ). The site of administration 
will be recorded.
Subjects (and/or their caregiver, if applicable) will self- administer mepolizumab liquid 
drug product in autoinjector for the first t ime immediatel y after being trained in its use at 
Visit 2 (i.e. the Start of Study  Visit). The training is designed to be representative of the 
instruction and training materials that will be provided once the device is commerciall y 
available. 
Three doses of mepolizumab drug product in autoinjector will be self -administered b y the 
subject/caregiver at 4 -weekly  intervals; 2 doses will be administered under observation in 
the clinic (at Visits 2 and 4).  The second in clinic administration (Visit 4) will not
include an y onsite training or other support, other than the Instructions for Use, which 
could assist the subject.  One dose will be administered outside the clinic and without 
observation (within 24 hours after attending the clinic for Visit 3). Followin g each 
injection, subjects will complete a patient diary  immediately  following, 1 -and 24 -hours 
after administration indicating the pain experienced and, for the unobserved dose 
administered at home following Visit 3, subjects/caregivers will complete a ch ecklist of 
the steps required to successfully  administer the injection. At the End of Study  Visit 
(Visit 5), subjects will be asked about their overall experience with the liquid drug 
product in autoinjector, including device performance and ease of use. 
Due to differences in the labelling requirements among regulatory  authorities around the 
world, two different labelling approaches will be included in this global study :  labelling 
that includes a pictogram plus standard labelling elements, or a standard l abelling without 
the pictogram.  The pictogram plus standard labelling elements is intended to satisfy  
requirements of the US Food and Drug Administration; while the standard labelling
(without pictogram) is intended to satisfy  requirements of Regulatory  Agencies outside of 
the United States.  English speaking subjects outside of the US can contribute to the 
cohort used to assess the US label.  All subjects at a given clinical trial site will utili se the 
same format of device label for all injections throug hout the study .  The assessment of 
injection success will be reported separatel y according to the format of labelling used.
Treatment A rms and Duration
The study  is single arm in which all subjects will receive mepolizumab 100 mg SC from 
the liquid drug pr oduct in autoinjector presentation.  Each subject will participate in the 
study  for up to 18 weeks and will have a Pre -screening visit (Visit 0), a Screening visit 
(Visit 1) and a 12- week Treatment Period (Visits 2 through 4) which concludes with End 
of St udy assessments (Visit 5) 4 weeks after the last dose of mepolizumab at Visit 4. 
2016N275054_0 4 CONFIDENTIA L
204959
12Type and Number of Subjects
Male or female subjects aged 12 years or older with severe eosinophilic asthma. Subjects 
must either have been receiving mepolizumab administered SC for the treatment of 
severe eosinophilic asthma every  4 weeks for at least 12 weeks prior to Visit 1 or, if not 
previously  using mepolizumab must be using , or have a requirement for, high dose 
inhaled corticosteroids plus an additional controller with a history  of 1 or more 
exacerbations requiring systemic corticosteroids in the 12 months prior to Visit 1.
Approximately  225 subjects will be screened to achieve 1 58 enrolled subjects with the 
aim of achieving 150completed/evaluable subjects. Approximate ly 100 subjects will use 
autoinjectors with labelling that includes a pictogram plus standard labelling elements 
and 50 subjects will use the standard labelling without the pictogram.
Sample Size Calculations and Statistical A nalyses
No formal sample size calculations were performed. Assuming a 30% screen failure rate, 
approximately  225
subjects will be screened in order to enrol 158 subjects (attempting at 
least one self -administration of mepolizumab). Assuming a dropout rate of up to 5% 
during the stud y, 158enrolled subjects should provide at least 150 subjects with complete 
study  data.
The number and percentage of subjects successfully  able to self -administer their doses 
will be reported separately  for the group of subjects using labelling that includes a 
pictogram plus standard labelling elements or the group using the standard labelling 
without the pictogram ,including 95% confidence intervals.  No hy pothesis testing will be 
performed.
2. INTRODUCTION
Mepolizumab (SB -240563) is a humanised monoclonal antib ody (IgG1, kappa, mAb) 
that blocks human interleukin -5 (hIL -5) from binding to the IL -5 receptor complex 
expressed on the eosinophil cell surface and thus inhibits signalling; neutralisation of IL -
5 with mepolizumab reduces blood, sputum and eosinophils.
Mepolizumab has recently  been approved in a number of markets including the United 
States (US), European Union (EU), Canada, Australia, Japan, South Korea, Switzerland 
and Taiwan for the treatment of severe eosinophilic asthma.  Mepolizumab is also under 
development for other indications, including the treatment of Chronic Obstructive 
Pulmonary  Disease (COPD), FIP1L1/PDGFR -negative hy pereosinophilic sy ndrome 
(HES) and eosinophilic granulomatosis with poly angiitis (EGPA) (i.e., Churg Strauss 
syndrome).
2.1. Stud yRationale
Mepolizumab for I njection is supplied as a sterile, single -use, preservative -free, 
lyophilised formulation (herein referred to as l yophilised drug product). This is the form 
that was used in the clinical development programmes and is the current marketed 
presentation for asthma (NUCALATM). Before use, a healthcare provider must 
2016N275054_0 4 CONFIDENTIA L
204959
13reconstitute each vial of lyophilised drug product with water for injection (WFI) using 
aseptic techniques. As part of the life cy cle of mepolizumab, a liquid drug product
(provided as a read y-to-use pre -filled sy ringe assembled into either a safety sy ringe or an 
autoinjector), Mepolizumab Injection, is being developed.  Administration of 
Mepolizumab I njection (herein referred to as liquid drug product in autoinjector) is 
intended to improve patient/physician convenience and enable home/self injection via 
caregivers and/or patients.
The changes to the liquid drug product site of manufacture, processing and formulation 
have been minimised. The liquid drug product has been as sessed against the ly ophilised 
drug product, prior to clinical evaluation, using comprehensive biochemical/biophy sical 
comparability  evaluations with comparability  between the two products being 
demonstrated. The likelihood of clinically  significant differ ences in the s ystemic 
exposure, efficacy , safet y and/or immunogenicit y of the liquid drug product in 
autoinjector or safet y syringe as compared with the reconstituted l yophilised drug product 
is considered to be low.  To provide further assurance of compar able exposure from the 
liquid drug products and the ly ophilised drug product, a single -dose pharmacokinetic 
(PK) comparability  study in healthy  subjects will be performed in parallel with this trial 
(Study  204958).   Thus, the primary  objective of this study  is to characteri se the degree of 
appropriate use of the autoinjector by a group of subjects representative (i. e., similar age, 
dexterity  and cognitive abilities, degree of training or experience with an autoinjector) of 
patients, likely  to use the au toinjector as aself-injected medicine . 
A separate study  (Study  
205667) will characteris e the appropriate use of the safet y syringe.
2.2. Brief Background
Mepolizumab binds with high affinity  to human IL -5 and blocks its binding to and the 
activation of the IL
-5 receptor (CD125).
Randomised, multi -centre, placebo -controlled exacerbation studies (MEA112997, 
MEA115588) and an Oral Corticosteroid (OCS) Reduction Study  (MEA115575) have 
demonstrated the efficacy  of mepolizumab and support the use of mepolizumab 100 mg 
subcutaneous (SC) every 4 weeks as an add -on therapy  for the treatment of severe 
eosinophilic asthma. Compared with placebo, mepolizumab has been shown to: 
Reduce the rate of clinically  significant exacerbations by  approximately  50%.  These 
results were replicated in studies MEA112997 and MEA115588.
Reduce the rate of exacerbations requiring hospitalisations and/or Emergency 
Department (ED) visits, with mean reductions ranging from 32% to 61%.
Produce statistically  significant and/or clinicall y relevant improvements in lung 
function based on forced expiratory  volume in one second (FEV 1), asthma control 
based on Asthma Control Questionnaire (ACQ -5), quality  of life based on St. 
George’s Respiratory  Questionnaire (SGRQ) and clinician and subject- rated overa ll 
response to therap y in the target population.  
Produce consistent reductions in blood eosinophil levels detected at Week 4 which 
were sustained for the duration of treatment.
2016N275054_0 4 CONFIDENTIA L
204959
14Additional details of the pharmacology , efficacy  and safet y can be found in t he 
Investigator Brochure (IB) [GSK Document Number CM2003/00010/12 ].
3. OBJECTIVE(S) A ND END POINT(S)
The aim of this study  is to assess the correct real-world use of the mepolizumab liquid 
drug product in autoinjector for the repeat self- administration of mepolizumab 
subcutaneousl y by determining the proportion of subjects with severe eosinophilic 
asthma who are successfully  able to self -administer a dose of mepolizumab. For the 
purposes of this study , ‘self -administration’ is defined as either the administration of 
mepolizumab liquid drug product in autoinjector by the subject themselves or by  their 
caregiver.
The objectives and endpoints associated with these objectives are outlined below:
Objectives Endpoints
Primary
To assess the use of the combination 
product, mepolizumab liquid drug 
product in autoinjector for the 
subcutaneous self -administration of 
mepolizumab by  subjects with severe 
eosinophilic asthmaProportion of subjects successfull y able 
to self -administer their observed third 
dose at Week 8
Secondary
To assess the use of mepolizumab 
liquid drug product in autoinjector 
outside the clinic settingProportion of subjects successfull y 
able to self -administer their 
unobserved second dose outside the 
clinic setting at Week 4
2016N275054_0 4 CONFIDENTIA L
204959
15Objectives Endpoints
Other
To assess the use of mepolizumab 
liquid drug product in autoinjector both 
inside and outside of the clinic setting
Toevaluate autoinjector use & 
functionality
To evaluate an y autoinjector injection 
errors/failures related to use or device 
performance
To characterise the subject experience 
of using the mepolizumab liquid drug 
product in autoinjector
To assess mepolizumab plasma trough 
concentrations following the SC 
administration of mepolizumab liquid 
drug product in autoinjector
To assess the pharmacodynamic effect 
following the SC administration of 
mepolizumab liquid drug product in 
autoinjector
To assess the freque ncy of asthma 
exacerbationsProportion of subjects successfull y able 
to self -administer their observed first 
dose at Week 0
Proportion of subjects successfull y able 
to self -administer both their unobserved 
second dose and observed third dose at 
Weeks 4 and 8
Proportion of subjects successfull y able 
to self -administer all three doses at 
Weeks 0, 4 and 8
Device usabilit y/functionality
questionnaire completed at the End of 
Study /Earl y Withdrawal Visit
Evaluation of user/device errors
Root cause anal ysis of each 
unsuccessful injection
Subject Exit I nterviews completed over 
the telephone after the End of 
Study /Earl y Withdrawal Visit
Mepolizumab plasma trough 
concentrations (Ctrough) at Weeks 4, 8 
and 12
Ratio to baseline of blood eosinophils 
at  Weeks 4, 8 and 12
Incidence of asthma exacerbations
2016N275054_0 4 CONFIDENTIA L
204959
16Objectives Endpoints
Safety
To evaluate the safet y and tolerability  of 
mepolizumab liquid drug product in 
autoinjectorIncidence and frequency  of Adverse 
Events / Serious Adverse Events 
including s ystemic reactions and 
injection site reactions
Clinically  significant change in 
haematological and/or clinical 
chemistry  parameters
Vital signs
12-lead electrocardiogram (ECG)
Incidence of immunogenicity
Level of self -reported pain 
immediately  following,1- and 24-
hours following each injection 
(patient diary )
4. STUDY DESIGN
4.1. Overall Design
This Phase III stud y will be an open- label, single arm, repeat -dose, multi -centre study  of 
mepolizumab liquid drug product in autoinjector (100 mg) administered SC every  4 
weeks in subjects with severe eosinophilic asthma. The study  is designed to evaluate the 
use of the autoinjector liquid drug product presentation by  severe eosinophilic asthma 
subjects (or their caregivers) for the SC administration of mepolizumab ( Figure 1).
2016N275054_0 4 CONFIDENTIA L
204959
17Figure 1 Study  Schematic
For the purposes of this study , ‘self -administration’ is defined as either the administration 
of mepolizumab liquid d rug product in autoinjector by the subject themselves or b y their 
caregiver. If applicable, only  one caregiver per subject will be permitted.
Subjects will receive 100 mg mepolizumab SC as a single injection that is self -
administered in the thigh, abdomen or administered in the upper arm (caregiver only ), 
using the liquid drug product in autoinjector presentation. The site of administration will 
be recorded.
Subjects (and/or their caregiver, if applicable) will self- administer mepolizumab liquid 
drug produc t in autoinjector for the first time immediatel y after being trained in its use at 
Visit 2 (i.e. the Start of Study  Visit). The training is designed to be representative of the 
instruction and training materials, including the Instructions for Use (IFU) th at will be 
provided once the device is commerciall y available [Note: the autoinjector is referred to 
as a ‘pre -filled pen’ in the IFU]. Each autoinjector will have labelling that includes a 
pictogram plus standard labelling elements, or a standard labelling without the pictogram 
dependant on the country in which it is being used.
Three doses of mepolizumab liquid drug product in autoinjector will be self -administered 
by the subject/caregiver at 4 -weekl y intervals; 2 doses will be administered under 
observat ion in the clinic (at Visits 2 and 4).  The second in clinic administration (Visit 4) 
will not include any  onsite training or support, other than the IFU, which could assist the 
subject.  One dose will be administered outside the clinic and without observa tion (within 
24 hours after attending the clinic for Visit 3). Following each injection, subjects will 
complete a patient diary , included in the Study  Reference Manual (SRM), and report the 
pain experienced immediately  following, 1 -and 24 -hours post injec tion. Observations 
about the injection will be recorded b y the investigator or designee for the doses 
administered in the clinic using an observer checklist. For the unobserved dose 
administered at home, a similar checklist detailing the steps required to successfully  

2016N275054_0 4 CONFIDENTIA L
204959
18administer the injection will be completed b y the subject/caregiver. All injections will be 
assessed for success based on:
Direct observation of the self- administration using the Observer Checklist if the 
mepolizumab dose was administered in the clinic, and inspection of the 
autoinjector
Subject/caregiver completed checklist and inspection of the returned autoinjector 
if the mepolizumab dose was administered outside the clinic
A self -administered injection is considered successful if the following criteria are met: 
Use of a correct injection site (abdomen/thigh or upper arm [caregiver onl y])
Full dose administration: subject pushes the autoinjector all the way  down and 
holds until either the second click, or the plunger stops moving and the i nspection 
window is filled with the y ellow indicator or pushes the autoinjector all the way  
down and holds for a total of 15 seconds
No observations are made with respect to the autoinjector, following inspection, 
which indicates the full dose has not been dispensed
If the above criteria are met, the investigator or designee will confirm the injection was 
successfull y delivered. 
Any unsuccessful injection will undergo a root- cause investigation, following a scripted 
approach, and evaluation to assess wheth er the unsuccessful injection was associated with 
the instructions / use of the device or whether it was associated with a device failure 
using the Autoinjector (Pen) Error/Failure Reporting Form, further details of which can 
be found in the SRM. All devic eswill be evaluated by  Device Engineering at 
GlaxoSmithKline (GSK), post- use, to assess overall performance and robustness of the 
device.
At the End of Study  Visit, subjects will be asked to record their overall experience with 
the autoinjector including device performance.
In all subjects, blood samples for both PK, haematology  assessment (which will include 
blood eosinophil count for the pharmacod ynamic effect assessment) and clinical 
chemistry  assessment will be collected at the time points indicated in the Time and 
Events Table (Section 7.1).
4.2. Treatment A rms and Duration
This is a single arm study in which all subjects will receive mepolizumab 100 mg SC 
every  4 weeks, using the liquid drug product in autoinjector presentation, for 12 weeks. 
Each subject will participate in the study  for up to 18 weeks (Visit 0 to the End of Study  
Visit (Visit 5) as described in Table 1
.
2016N275054_0 4 CONFIDENTIA L
204959
19Table 1 Study  Phases
Phase Phase Title Duration Description
1 Pre-screening 0 to 2 weeks At the Pre -screening Visit (Visit 0), details 
about the study  and procedures will be 
explained through the informed consent 
process. The Pre -screening Visit can occur 
on the same day  as the Screening Visit 
(Visit 1) but must be completed prior to 
initiatin g any Visit 1 procedures. 
2 Screening 1 to 4 weeks Subjects will be assessed for eligibility  at 
the Screening Visit (Visit 1). Blood draws 
will be taken for assessments of liver 
function and to determine blood 
eosinophil levels in subjects not 
previously  using mepolizumab and who 
do not meet the historical blood eosinophil 
criterion. 
3 Treatment 12 weeks At Visit 2 (Week 0) those subjects who 
continue to meet the eligibility  criteria and 
the continuation to treatment criteria (see 
Section 5.3) will receive mepolizumab 
100 mg SC every  4 weeks for a total of 3 
doses. 
The treatment period will conclude with 
subjects completing End of Study  Visit 
(Visit 5) assessments approximately  4 
weeks after the subject was adminis tered 
their last dose of study  treatment at Visit 
4. 
A subject who adheres to the study  treatment and assessment schedule (as detailed in 
Time and Events Table, Section 7.1) will be considered to have completed the study  if 
they complete all of the assessments at the End of Study  visit (Visit 5). A subject who 
permanentl y discontinues study  treatment earl y will be withdrawn from the study after 
completing the Ear ly Withdrawal visit (See Time and Events Table, Section 7.1).
Subjects receiving mepolizumab prior to the study  will be advised to continue with their 
pre-study  mepolizumab treatment following completion of the assessments at the End of 
Study /Earl y Withdrawal visit. Subjects not receiving mepolizumab prior to the start of 
the study  will have mepolizumab treatment stopped at the End of Study /Early  
Withdrawal visit an d will receive appropriate care and treatment as determined by their 
treating ph ysician.
2016N275054_0 4 CONFIDENTIA L
204959
204.3. Type and Number of Subjects
Approximately  225 subjects with severe eosinophilic asthma will be screened in order to 
achieve 158 enrolled subjects (attempting at least one self
-administration of 
mepolizumab) and 150 subjects with complete study  data. Approximately  100 subjects 
willuse autoinjectors with labelling that includes a pictogram plus standard labelling 
elements and 50 subjects will use the standard labelling without the pictogram.
4.4. Design Justification
An open -label, repeat -dose, single arm, multi -centre study  design is deemed appropriate 
to evaluate self -administration of mepolizumab liquid drug product in autoinjector in 
subjects with severe eosinophilic asthma. Theprimary  purpose ,andresultant study
design is to assess the appropriate use of the autoinjector in a real world use setting.  
Participants are intended
to be broadl y representative of patients and caregivers (i.e., 
similar age, dexterity  and cognitive abilities, degree of training or experi ence with an 
autoinjector) who may  use the autoinjector, either for the treatment of severe eosinophilic 
asthma or ,potentially ,other approved indications. In addition , safet y outcomes , 
immunogenicit y, pharmacokinetics and pharmacody namics will be also be characteri sed 
in this study .
A population of subjects with severe eosinophilic asthma either currentl y receiving or not 
currentl y receiving commerciall y available mepolizumab SC at study  entry  (Visit 1) was 
selected to reflect the intended population in “real world” use conditions. Subjects not 
currentl y receiving mepolizumab will have a history of ≥1 exacerbations requiring 
treatment with sy stemic corticosteroids in the previous 12 months while using ,or hav ing
a requirement for ,high dose inhaled corticosteroids ( ICS)plus a second controller.
Due to differences in the labelling requirements among regulatory  authorities around the 
world, two different labelling approaches will be included in this global study :  labelling 
that includes a pictogram 
plus standard labelling elements, or a standard labelling without 
the pictogram.  The pictogram plus standard labelling elements is intended to satisfy  
requirements of the US Food and Drug Administration; while the standard labelling 
(without pictogram) is intended to satisfy  requirements of Regulatory  Agencies outside of 
the United States.  English speaking subjects outside of the US can contribute to the 
cohort used to assess the US label.  All subjects at a given clinical trial site will utilise the 
same format of device label for all injections throughout the study .  The assessment of 
injection success will be reported separatel y according to the format of labelling used.
The standardised training provided in this study  will be representative of the inst ruction 
and training materials that will be given once the device is commercially  available for 
use. Subjects will be observed self -administering liquid drug product from the 
autoinjector immediatel yafter being trained in its use at Visit 2 (Week 0) . Subj ectswill 
self-administer at 4-weekly  intervals, either at the clinic or outside of the clinic (Time and 
Events Table, Section 7.1). The primary  endpoint of the study  will be assessed under 
observation at Visit 4, 8 weeks after the subject received training in the use of the 
autoinjector.
2016N275054_0 4 CONFIDENTIA L
204959
21With regards to the pharmacokinetic and pharmacody namic assessments, it is 
acknowledged that mepolizumab exposure will not be at s teady-state after the first and 
second SC doses (administered at Visits 2 and at home following Visit 3, respectively) in 
those subjects not previously  receiving mepolizumab treatment at Visit 1; however, 
mepolizumab plasma concentration at the end of the dosing interval (Ctrough) 
measurements can be compared with historical data. L ikewise data from the Phase III 
study  MEA115588 showed that in subjects previously  not treated with mepolizumab, the 
reduction in blood eosinophil count at the end of the dosing interval following the first 
SC dose of mepolizumab (i.e. pre -steady -state) was close to the reduction observed at the 
end of the dosing interval following the eighth SC dose of mepolizumab (i.e. at stead y-
state). Therefore, in those subjects not receiving mepolizumab treatment at Visit 1, 
assessing the pharmacody namic effect of mepolizumab is still of interest. 
4.5. Dose Justification
The 100 mg dose of mepolizumab liquid drug product in autoinjector will match the dose 
of reconstituted l yophilised drug produc t (the currently  marketed form).
4.6. Benefit:Risk A ssessment
Summaries of findings from both clinical and non-clinical studies conducted with 
mepolizumab (SB -240563) ly ophilised drug product can be found in the Investigator’s 
Brochure [GSK Document Number CM2003/00010/12 ].  The following section outlines
the key  risks, risk assessment and mitigation strategy for this protocol based on 
mepolizumab ly ophilised formulation.  The safety  profile of the mepolizumab liquid 
formulation is anticipated to be similar to the ly ophilised formulation.  
2016N275054_0 4 CONFI DENTIA L
204959
224.6.1. Risk A ssessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP)
Risk of Sy stemic Reactions including 
allergic reactionsBiopharmaceutical products administered 
subcutaneousl y ma y elicit sy stemic (e.g. 
hypersensitivity ) and local site reactions.
In the placebo controlled severe asthma 
studies both acute and delay ed sy stemic 
reactions including h ypersensitivity  have
been reported following administration of 
mepolizumab with incidence rates similar 
between mepolizumab and placebo -treated 
subjects:
54/915 subjects or 6% in the 
mepolizumab [all doses combined] 
group 
7/263 subjects or 3% in the 
mepolizumab 100 mg SC gr oup
12/344 subjects or 3% in the 
mepolizumab  75 mg  intravenous (IV) 
group 
20/412 subjects or 5% in the placebo 
group. 
The most common sy mptoms reported with 
any systemic reaction included headache, 
rash, pruritus, fatigue, and dizziness. While Daily  monitoring of serious adverse events 
(SAEs) by  medical monitor; regular 
systematic review of adverse event 
(AE)/SAE data from ongoing studies b y the 
GSK study  team and/or safet y review team. 
Customised AE and SAE case report form 
(CRF) utilised for targeted collection of 
information for s ystemic reaction adverse 
events.
Use of Joint National I nstitute of Allergy  
and Infectious Disease (NIAID)/Food 
Allergy  and Anaphy laxis Network (FAAN) 
2nd Sy mposium on Anaphy laxis to collect 
data on reports of anaph ylaxis (see 
Appendix 2 ).
Subjects are monitored in clinic for at least 
1 hour following self -administration of 
mepolizumab at the clinic. For 
administration at home, subjects will be 
instructed to call the investigator and/or go 
toan Emergency Department for any  
unusual sy mptoms (e.g. sy mptoms 
2016N275054_0 4 CONFI DENTIA L
204959
23Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
rare, se rious s ystemic reactions including 
anaph ylaxis have been reported.
Systemic reactions reported to date across 
the mepolizumab programme are 
summarized in the IB “Adverse Events of 
Special Interest” section; see also ‘Special 
Warnings and Special Precautio ns for Use’ 
section located in Section 6 titled ‘Summary  
of Data and Guidance for the I nvestigator’ 
[GSK Document 
Number CM2003/00010/12 ].concerning for h ypersensitivity  include skin 
rash [hives] or redness, swelling of the face 
or mouth, becoming wheezy , coughing or 
having difficulty  in breathing and/or feeling 
weak or light h eaded).
Injection site reactions In the placebo controlled severe asthma 
(PCSA) studies the incidence of local site 
reactions with SC administration of 
mepolizumab was higher on mepolizumab 
100 mg SC group (21/263 or 8%) compared 
to mepolizumab 75mg IV (1 0/344 or 3%) or 
placebo (13/412 or 3%). Sy mptoms 
included pain, ery thema, swelling, itching, 
and burning sensation. 
Local injection site reactions reported to 
date across the mepolizumab program are 
summarized in the IB “Adverse Events of 
Special Interest ” section; see also Section 6 
titled ‘Summary  of Data and Guidance for 
the Investigator’ [GSK Document Daily  monitoring of serious adverse events 
(SAEs) by  medical monitor; regular 
systematic review of adverse event 
(AE)/SAE data from ongoing studies b y 
GSK study  team and/or sa fety review team. 
Customised AE and SAE case report form 
(CRF) utilised for targeted collection of 
information for local injection site reaction 
adverse events.
Pain assessment will also be done utilizing 
visual analog scale, in the patient diary , 
immedia tely after injection, 1 hour after 
injection and 24 hours ( 4hours) after 
injection.
2016N275054_0 4 CONFI DENTIA L
204959
24Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Number CM2003/00010/12 ].
Potential risk of immunogenicity Biopharmaceutical products may  elicit anti -
drug antibody  (ADA) and neutralising 
antibody  (NAb), which have the potential to 
modulate pharmacokinetic (PK), 
pharmacod ynamic (PD) or produce adverse 
reactions. 
Mepolizumab has low immunogenic 
potential. Both incidence and titer data from 
completed studies demonstrate a low risk 
for loss of efficacy  associated with AEs 
and/or altered PK/PD. I mmunogenicit y data 
reported to date across the mepolizumab 
development program are summarized in 
the IB; See Section 5.4 ‘ Clinical 
Immunogenicit y’ and a summary  of 
immunogenicit y findings in Section 6 
‘Other Potentially  Clinically  Relevant 
Information for the Investigator’ [GSK 
Document Number CM2003/00010/12 ].Blood samples will be collected for 
detection of both ADA and NAb.
Study Procedures
Injuries due to accidental needle sticks The autoinjector has been designed and 
verified to compl y with ISO23908  ‘Sharps 
injury  protection –Requirements and test 
methods – Sharps protection features for 
single -use hy podermic needles, introducers 
for catheters and needle s used for blood The subject will be educated by  the staff 
prior to self -administration and their first 
scheduled dose will be supervised in the 
clinic by the staff. Additionally , the IFU 
will instruct the subject on the safe use of 
2016N275054_0 4 CONFI DENTIA L
204959
25Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
sampling’ the device.
Aplastic needle cover shields the needle 
before and after injection to minimise the 
potential for needle stick injuries.
The needle is protected by a guard, which 
following injection, re- extends and locks in 
place to cover the needle.
2016N275054_0 4 CONFIDENTIA L
204959
264.6.2. Benefit A ssessment
The primary  purpose of this study  is to assess the appropriate use of the autoinjector in a 
real world use setting.  Participants are intended to be broadl y representative of patients 
and caregivers (i.e., similar age, dexterity  and cognitive abilities, degree of training or 
experience with an autoinjector) who may use the autoinjector, either for the treatment of 
severe eosinophilic asthma or, potentially , other approved indic ations. Efficacy  is not 
being assessed in this study  as the efficacy  of mepolizumab in severe eosinophilic asthma 
has previousl y been demonstrated in prior studies [ Haldar , 2009; Nair , 2009; Pavord, 
2012
; Bel, 2014; Orte ga, 2014].   The autoinjector is intended to provide a more 
convenient mode of delivery  from previous mepolizumab administration and potentially  
gives patients an option to self -administer mepolizumab at home.
4.6.3. Overall Benefit:Risk Concl usion
Current data from mepolizumab preclinical and clinical development indicate the ability  
of mepolizumab to inhibit IL- 5 leading to consistent reduction in blood eosinophils, with 
demonstration of clinical benefit in the treatment of conditions associa ted with 
eosinophilic inflammation, such as asthma. Data from the Phase III asthma programme 
with mepolizumab demonstrates, compared to placebo, a reduction in asthma 
exacerbations, improvements in asthma control and quality  of life (as measured b y the 
ACQ and SGRQ, respectively ), improvements in lung function and a reduction in oral 
corticosteroid use in those subjects on chronic OCS treatment. To date, the safet y profile 
of mepolizumab has been favourable and the benefit/risk profile remains positive in 
patients with severe asthma. The change in drug product presentation from a ly ophilised 
drug product to a liquid drug product in an autoinjector is not anticipated to alter the 
overall benefit:risk. The ability  of subjects to self -administer treatment will be closel y 
observed in the clinic and subjects will be instructed to seek medical attention if they  
experience an y abnormal sy mptoms following administration at home, away  from the 
clinic. 
5. SELECTION OF STUDY P OPULA TION A ND 
WITHDRA WAL CRITERIA
Specific inf ormation regarding warnings, precautions, contraindications, adverse events, 
and other pertinent information on the GSK investigational product or other study  
treatment that may  impact subject eligibility  is provided in the IB/IB supplement(s) .
Deviations from inclusion and exclusion criteria are not allowed because they can 
potentially  jeopardise the scientific integrity  of the study , regulatory  acceptability  or 
subject safet y. Therefore, adherence to the criteria as specified in the protocol is essential.
5.1. Inclusion Criteria
A subject will be eligible for inclusion in this study onl y if all of the following criteria 
apply :
2016N275054_0 4 CONFIDENTIA L
204959
27AGE
1.Age: At least 12 years of age inclusive, at the time of signing the informed consent.
[For those countries where local regulations permit enrolment of adults only , subject 
recruitment will be restricted to those who are 18 years of age]
TYPE OF SUBJECT AND DIAGNOSI S INC LUDING DISEASE SEVERI TY 
2.Asthma: A ph ysician diagnosis of asthma for ≥2 years that meets the National Heart, 
Lung and Blood Institute guidelines [ National heart, lung and blo od institute (NIH) ,
2007] or Global I nitiative for Asthma (GINA) guidelines [ GINA , 2015]
3.Mepolizumab treatment :
a.Not receiving mepolizumab treatment at Visit 1
(NB: these subjects must also meet inclusion criteria 4, 5, 6 and 7).
OR
b.Receiving 100 mg SC mepolizumab administered for the treatment of 
severe eosinophilic asthma every  4 weeks for at least 12 weeks prior to 
Visit 1.
The following inclusion criteria are only applicable to those subjects NOT receiving 
mepolizumab treatment at Visit 1:
4.Eosinophilic asthma : A high likelihood of eosinophilic asthma as per the required 
‘Continuation to Treatment’ - Criterion 2.
5.Inhaled Corticosteroid: A well -documented requirement for regular treatment with
high dose inhaled corticosteroid (ICS) i n the 12 months prior to Visit 1 with or 
without maintenance oral corticosteroids (OCS).
For subjects 
18 years old:
ICS dose must be ≥880 mcg/day  fluticasone propionate (FP) (ex-
actuator) or equivalent daily .
For ICS/long -acting -beta-2-agonist (LABA) combination 
preparations, the highest strength approved maintenance dose in the 
local country  will meet this I CS criterion.
For subjects  12 to 17 years old:
ICS dose must be ≥
440 mcg/day  FP (ex -actuator) or equivalent dail y.
For ICS/LABA combination preparations, the m id-strength approved 
maintenance dose in the local country  will meet this I CS criterion.
(Subjects will be permitted to be enrolled without continuous high dose ICS 
providing the subject was receiving continuous ICS and the Investigator attests that 
the subject should have been treated with high dose ICS to mitigate the risk of 
exacerbations but financial or tolerance issues prevent
edthe use of high- dose ICS.
Such subjects should be discussed with GSK Medical Mo nitor prior to enrolment )
2016N275054_0 4 CONFIDENTIA L
204959
286.Controller Medication: Current treatment with an additional controller medication, 
besides I CS, for at least 3 months or a documented failure in the past 12 months of an 
additional controller medication [e.g., long -acting beta -2-agonist (LABA), 
leukotriene receptor antagonist (LTRA), or theophy lline] for at least 3 successive 
months.  
7.Exacerbation history: Previously  confirmed history  of one or more exacerbations 
requiring treatment with systemic corticosteroid (CS) [intramuscula r (IM), 
intravenous, or oral] in the 12 months prior to Visit 1, despite the use of high -dose 
ICS.  For subjects receiving maintenance CS, the CS treatment for an exacerbation 
must have been a two -fold dose increase or greater. 
WEI GHT
8.Body weight : A minimum  40 kg at Visit 1
SEX
9.Gender: Male or Female
Females : 
A female subject is eligible to participate if she is not pregnant (as confirmed by  a 
negative urine human chorionic gonadotrophin (hCG) test), not planning to become 
pregnant during the time of study  participation (and up to 16 weeks after the last dose), 
not lactating, and at least one of the following conditions applies:
a.Non-reproductive potential defined as:
Pre-menopausal females with one of the following:
Documented tubal ligation
Documented h ysteroscopic tubal occlusion procedure with follow -up 
confirmation of bilateral tubal occlusion 
Hysterectomy
Documented Bilateral Oophorectom y
Postmenopausal female (see Appendix 3 for specific criteria).
b. Reproductive potential and agrees to follow one of the options listed in the Modified 
List of Highl y Effective Methods for Avoiding Pregnancy in Females of 
Reproductive Potent ial (FRP) (see Appendix 3 ) from 30 day s prior to the first dose of 
study  medication and until 16 weeks after the last dose of study  medication and 
completion of the End of Study /Earl y Withdrawal visit.
The investigator is responsible for ensuring that subjects understand how to properl y use 
these methods of contraception.
2016N275054_0 4 CONFIDENTIA L
204959
29INFORMED CONSENT
10.Informed Consent: Capable of giving signed informed consent which includes 
compliance with the requirements and restrictions listed in the consent form and in 
this protocol.
5.2. Exclusion Criteria
A subject will not be eligible for inclusion in this study  if an y of the following criteria 
apply :
CONCURRENT CONDITIONS/MEDI CAL  HISTORY (INCLUDES LIVER 
FUNCTION AND QTc INTERVAL) 
1.Concurrent Respiratory Disease: Presence of a known pre -existing, clinically  
important lung condition other than asthma.  This includes current inf ection, 
bronchiectasis, pulmonary fibrosis, bronchopulmonary  aspergillosis, or diagnoses of 
emphy sema or chronic bronchitis (chronic obstructive pulmonary disease other than 
asthma) or a history  of lung cancer.
2.Eosinophilic Diseases: Subjects with other co nditions that could lead to elevated 
eosinophils such as Hy pereosinophilic Sy ndromes, including Churg -Strauss 
Syndrome, or Eosinophilic Esophagitis.  Subjects with a known, pre -existing 
parasitic infestation within 6 months prior to Visit 1 are also to be excluded.
3.Malignancy: A current malignancy  or previous history  of cancer in remission for 
less than 12 months prior to screening (Subjects that had localized carcinoma of the 
skin which was resected for cure will not be excluded). 
4.Immunodeficiency: A know n immunodeficiency  (e.g. human immunodeficiency  
virus – HIV), other than that explained by  the use of corticosteroids taken as therap y 
for asthma.
5.Other Concurrent Medical Conditions: Subjects who have known, pre -existing, 
clinically  significant cardiovascular, endocrine, autoimmune, metabolic, 
neurological, renal, gastrointestinal, hepatic, haematological or an y other system 
abnormalities that are uncontrolled with standard treatment.
6.Liver Disease: Known, pre -existing, unstable liver disease (as defined b y the 
presence of ascites, encephalopathy , coagulopathy , hypoalbuminaemia, esophageal 
or gastric varices or persistent jaundice), cirrhosis, and known biliary  abnormalities 
(with the exception of Gilbert’s sy ndrome or as ymptomatic gallstones).
7.ECG Assessme nt: QT interval corrected for heart rate by  either Fridericia’s or 
Bazett’s formula QTc(F)/QTc(B) ≥450msec or QTc(F)/QTc(B) ≥480 msec for 
subjects with Bundle Branch Block at Visit 1.
CONCOMI TANT MEDICATIONS
8.Xolair: Subjects who have received omalizumab within 130 day s of Visit 1.
2016N275054_0 4 CONFIDENTIA L
204959
309.Other Monoclonal Antibodies not including mepolizumab: Subjects who have 
received an y monoclonal antibody (other than Xolair) to treat inflammatory disease 
within 5 half -lives of Visit 1.
10.Investigational Medications: Subjects who have received treatment with an 
investigational drug, other than mepolizumab within the past 30 day s or five terminal 
phase half -lives of the drug whichever is longer, prior to visit 1 (this also includes 
investigational formulations of marketed produc ts) or experimental anti -
inflammatory  drugs (non biologicals) in the past 3 months.
11.Chemotherapy :Subjects who have received chemotherapy  within 12 months prior 
to Visit 1.
REL EVANT HABITS
12.Alcohol/Substance Abuse: A history  (or suspected history ) of alcohol misuse or 
substance abuse within 2 years prior to Visit 1.
CONTRAINDICATIONS 
13.Hypersensitivity: Subjects with hy persensitivity  to mepolizumab or to any  of the 
excipients (sodium phosphate, citric acid, sucrose, EDTA, poly sorbate 80).
DIAGNOSTIC ASSESSMENTS AND OTHER CRI TERIA
14.Adherence: Subjects who have known evidence of lack of adherence to controller 
medications and/or ability to follow ph ysician’s recommendations.
5.3. Continuation to Treatment Criteria
At Visit 2, those subjects who c ontinue to meet the inclusion/exclusion criteria and who 
meet the continuation to treatment criteria will commence the stud y treatment phase until 
the target of approximately  158 enrolled subjects is reached.  
In order to receive study  treatment subjects must have fulfilled all inclusion and 
exclusion criteria described in Section 5.1and Section 5.2. I n addition to the following:
REQUI RED CRI TERIA TO START TREATMENT
1.Liver Function: At Visit 2, ALL study  subjects must fulfil the following additional 
criteria in order to be eligible for study  treatment:
Liver Function Tests : obtained at Visit 1:
oAlanine aminotransferase (ALT) ≤2x ULN (upper limit of normal)
oBilirubin ≤1.5x ULN (isolated bilirubin >1.5x ULN is acceptable if 
bilirubin is fractionated and direct bilirubin <35%)
2.Eosinophilic Phenotype : At Visit 2, study  subjects th at were NOT receiving 
mepolizumab treatment at Visit 1 must fulfil the following additional criteria in order 
2016N275054_0 4 CONFIDENTIA L
204959
31to be eligible for study  treatment:
Airway  inflammation characterised as eosinophilic in nature as indicated by  
one of the following:
a)A peripheral blood eosinophil count of 300 cells/ L that is related to 
asthma demonstrated in the past 12 months prior to Visit 1.
OR
b) A peripheral blood eosinophil count of 150 cells/ L at Visit 1 that is    
related to asthma.
5.4. Pre-Screening/Screening Failures
A subject will be assigned a subject number at the time the informed consent is signed.
A subject who is assigned a subject number at Visit 0 but does not have any  screening 
Visit 1 procedures will be considered a pre-screen failure.
Screen failures will be defined as those subjects who complete at least one Visit 1 
(Screening) procedure but do not attempt to self -administer a dose of mepolizumab.
The following information will be collected in the electronic case re port (eCRF) for 
subjects who are pre -screen, and screen failures:
Date of Informed Consent Form (ICF) signature
Demographic information including race, age and gender
Child bearing status assessment for all female subjects of reproductive potential 
Subjec t number
Details of asthma medications within 3 months of the pre- screening Visit 0
Details of asthma exacerbations during the pre- screening period
Serious Adverse Event information only for any  SAE considered as related to 
study  participation (e.g. protoc ol mandated procedures, invasive tests or change 
in existing therap y) or related to a GSK concomitant medication
Investigator signature page
In order to ensure transparent reporting of screen failure subjects, meet the Consolidated 
Standards of Reporting T rials (CONSORT) publishing requirements, and respond to 
queries from Regulatory  authorities, a minimal set of screen failure information is 
required including Demograph y, Screen Failure details, Eligibility Criteria, and Serious 
Adverse Events (see Section 7.7.1).
2016N275054_0 4 CONFIDENTIA L
204959
325.5. Withdrawal/Stopping Criteria
A subject may  withdraw from study  treatment at any  time at his/her own request, or may  
be withdrawn at an y time at the discret ion of the investigator for safet y, behavioural, or 
administrative reasons. If a subject withdraws from the study , he/she may  request 
destruction of an y samples taken, and the investigator must document this in the site 
study  records . As the aim of this st udy is to evaluate the use of the mepolizumab liquid 
drug product, in autoinjector presentation, for delivery  of mepolizumab, subjects who 
permanentl y withdraw from study  treatment will also be withdrawn from the study  (see 
Section 5.5.1). Reasons for premature discontinuation of study  treatment will be captured 
in the CRF.
5.5.1. Withdrawal from the Study
Subjects who have withdrawn from the study  should complete assessme nts for the Early  
Withdrawal Visit, 4 weeks after the last dose of mepolizumab (see Time and Events 
Table, Section 7.1).
A reason for the withdrawal from the study  must be captured in the eCRF.
A subject must be discontinued if any of the following criteria are met:
Withdrawal of consent
Lost to follow -up
A subject will also be withdrawn from the study , in consultation with the medical 
monitor and principal investiga tor, if any  of the following stopping criteria are met:
Laboratory  parameters: Clinically  important changes in laboratory  parameters 
identified
ECG: Clinically  significant abnormality  identified during the stud y that meet the 
QTc stopping criteria describe d in Section 5.5.3
Liver Chemistry : Meets any  of the Liver chemistry  stopping criteria (see Section 
5.5.2 and Appendix 4
Pregnancy : Positive pregnancy  test (see 
Appendix 3 ). Pregnancy  and pregnancy  
outcomes of subjects exposed to mepolizumab will be followed
The following actions must be taken in relation to a subject who fails to attend the clinic 
for a required stud y visit:
The site must attempt to contact the subject and re
-schedule the missed visit as 
soon as possible. 
The site must counsel the subject on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the subject wishes to and/or should 
continue in the study . 
2016N275054_0 4 CONFIDENTIA L
204959
33In cases where the subject is deemed ‘lost to follow up’, the investigator or 
design ee must make every  effort to regain contact with the subject (where 
possible, 3 telephone calls and if necessary a certified letter to the subject’s last 
known mailing address or local equivalent methods). These contact attempts 
should be documented in the subject’s medical record. 
Should the subject continue to be unreachable, only then will he/she be considered 
to have withdrawn from the study  with a primary  reason of “Lost to Follow -up”. 
5.5.2. Liver Chemistry Stopping Criteria
Liver chemistry stopping and in creased monitoring criteria have been designed to 
assure subject safet y and evaluate liver event etiology (in alignment with the Food and 
Drug Administration [FDA] premarketing clinical liver safet y guidance). 
http://www.fda.gov/downloads/Drugs/GuidanceCom plianceRegulatoryInformation/Guid
ances/UCM174090.pdf
Liver Chemistry Stopping and Increased Monitoring Algorithm
Continue Study Treatment 
Discontinue Study Treatment  Plus 
Biliru bin≥2x
ULN (>35% 
direct) or plus
INR>1.5, if 
measur ed*
Possi ble  
Hy’sLawALT≥3xULNALT
≥8xULNPlus
Symptoms  of 
liver injury
or 
hyper sensitivityNo
Yes
Yes YesNo No NoSee algor ithm 
for continued 
therapy with 
increase d liver 
chemi stry 
monitoring
Yes
*INR value not applicable to subjects on anticoagu lants ALT 
≥3xULN 
but 
<8xULNYes
Must  refer to Liver Safety Requi red Actions and Fol low up Asses smen ts section in the Appendi x
Repor t as an SAE if possible Hy’sLaw case:  ALT≥3xUL N and  Biliru bin≥2x ULN (>35% direct)  or 
INR>1.5, if measur ed*
2016N275054_0 4 CONFIDENTIA L
204959
34Liver Chemistry Increased Monitoring Algorithm with Continued Therapy for ALT 
3xULN but <8xULN
Required actions and follow- up assessment f or all subjects who meet liver chemistry  
stopping or monitoring criteria are defined in Appendix 4 .
5.5.2.1. Study  Treatment Restart or Rechallenge
Study  treatment restart or rechalle nge after liver chemistry  stopping criteria are met, by  
any subject participating in this study , is not allowed.
5.5.3. QTc Stopping Criteria
The same QT correction formula must be used for each individual subject to 
determine eligibility  for and discontinuation from the study .  This formula may  
not be changed or substituted once the subject has been enrolled.  For example, if 
a subject is eligible for the protocol based on on QT interval corrected for heart 
rate b y Bazett’s formula (QTcB), then QTcB must be used for discontinuation of 
this individual subject as well.
Once the QT correction formula has been chosen for a subject’s eligibility , the 
same formula must continue to be used for that subject for all QTc data being 
collected for data analysis .  Safety  ECGs and other non- protocol specified 
ECGs are an exception.  
The QTc should be based on single or averaged QTc values of triplicate 
electrocardiograms obtained over a brief (e.g., 5 -10 minute) recording period. 
For example if a routine ECG demonstrates a prol onged QT, obtain 2 more Continue Study Treatm ent   and   Monitor Liver Chemistry
Discontinue Study Treatment ALT≥5xULN 
but <8xULN
+ bili<2xULN +
no sy mptoms
NoMust  refer to Liver Safety Requi red Actions and Follow up Asses sments section in the Appendi x
YesALT ≥3xULN 
but <5xULN
+ bili<2xULN  +
no sy mptomsAble to 
monitor  
weekly 
for  ≥2 
weeksPersists for 
≥2 weeks  
or other 
stop ping 
criteria   
met
NoYes Yes
YesNo No
Able to 
monitor  
weekly 
for  ≥4 
weeksPersists for 
≥4 weeks  
or other 
stop ping 
criteria   
metNo Yes Yes Yes YesALT ≥5xULN ALT <5xU LN 
Yes Yes
*INR value not applicable to subjects on anticoagulants Must  refer to Liver Safety Requi red Actions and Follow up Asses sments section in the Appendi x
Repor t as an SAE if possible Hy’sLaw case:  ALT≥3xUL N and  Bilirubin≥2xULN (>35% direct)  or 
INR>1.5, if measur ed*
2016N275054_0 4 CONFIDENTIA L
204959
35ECGs over a brief period and then use the averaged QTc values of the 3 ECGs 
to determine whether patient should be withdrawn from the study .
A subject who meets either of the bulleted criteria below will be withdrawn from the 
study :
QTc >500 msec OR Uncorrected QT >600 msec
Change from baseline (Visit 2) of QTc >60 msec
For patients with underl ying bundle branch block , follow the discontinuation criteria 
listed below:
Baseline (Visit 2) QTc with Bundle 
Branch BlockDiscontinuation QTc with Bundle 
Branch Block
<450 msec >500 msec
450 –480 msec ≥530 msec
5.6. Subject and Study  Completion
A completed subject is one who has completed the End of Study  (Week 12) visit.
The end of the stud y is defined as the last subject’s last visit.
6. STUDY TREA TMENT
6.1. Investigational Product and Other Study  Treatment
The term ‘stud y treatment’ is used throughout the protocol to describe the mepolizumab 
drug product in autoinjector received b y the subject as per the protocol design. 
Mepolizumab liquid drug product will be supplied by  GSK in Ty pe I glass sy ringes with 
staked needles (1/2 inch x 29 gauge thin wall), sealed with latex -free rubber plungers.  
These will be assembled in single use, disposable autoinjectors to enable automatic 
delivery  of the drug product. Each device will deliver 100mg mepolizumab in 1.0mL .  
The formulation contains sodium phosphate, citric acid, sucrose, EDTA and poly sorbate 
80.
2016N275054_0 4 CONFIDENTIA L
204959
36Study Treatment
Product name: Mepolizumab (NUCALA) (SB240563)
Device: Prefilled syringe contained within an autoinjector
Formulation description: 100 mg/mL mepolizumab with sodium phosphate, citric acid, 
sucrose EDTA and polysorbate 80
Dosage form: Sterile, liquid formulation
Unit dose 
strength(s)/Dosage level(s):100 mg/mL; 1.0mL (deliverable)
Route of Administration SC injection
Dosing instructions: SC dose in thigh, abdomen or upper arm every 4 weeks
Physical description: 
mepolizumabClear to opalescent, colourless to pale yellow sterile solution for 
SC injection in a single -use, prefilled s yringe contained within an 
autoinjector
Physical description of 
injection device:Single use, disposable autoinjector assembled with the prefilled 
syringe containing the drug product. The autoinjector enables 
automatic delivery of the drug product under t he power of a 
spring mechanism following activation of the device. Start and 
end of injection clicks inform the user of correct use. A plastic 
needle cover shields the needle before and after injection to 
minimise the potential for needle stick injuries.
Manufacturer/source of 
procurement:Prefilled syringe : Prefilled syringe components are procured 
from Becton Dickinson.  Prefilled syringe is filled with drug 
product and assembled at GSK, Barnard Castle, UK.
Autoinjector: The autoinjector components are manufactured by 
Ypsomed AG and assembled with the prefilled syringe at GSK, 
Barnard Castle, UK.
6.2. Medical Devices
The GSK manufactured medical devices (or devices manufactured for GSK by  a third 
party ) provided for use in this study  are injection devices: a prefilled s yringe contained 
within an autoinjector. The devices used in the study  are representative of the devices and 
regionally  appropriate device product labeling planned to be marketed for the product.
The components that comprise the prefilled s yringe, including glass barrel with prestaked 
needle and plunger are sourced from Becton Dickinson.  The prefilled s yringe is filled 
and assembled at GSK, Barnard Castle.  
The autoinjector components are manufactured b y Ypsomed AG.  The autoinjector 
components are assembled with the prefilled s yringe at GSK, Barnard Castle.
The IFU of these injection devices are provided in the SRM. The instructions were 
developed and optimised as a result of formative human factors studies and are 
representative of those tha t are planned for the product.
2016N275054_0 4 CONFIDENTIA L
204959
37GSK medical device incidents, including those resulting from malfunctions of the device, 
must be detected, documented, and reported b y the investigator throughout the study –
see Section 7.7.3.
6.3. Treatment A ssignment
All subjects will be assigned to the same treatment at Visit 2 (Week 0).
6.4. Blinding
This will be an open -label, single arm stud y. 
6.5. Packaging and Labe lling
The contents of the label will be in accordance with all applicable regulatory  
requirements . The autoinjector will either be labelled with a pictogram plus standard 
labelling elements or standard labelling without the pictogram.
6.6. Preparation/Handling/Storage/A ccountability
No special preparation of study  treatment is required.
Study  treatment must be dispensed or administered according to procedures described 
herein.  Onl y subjects enrolled in the study may receive stud y treatment.  Only  authorised 
site staff may  supply  study  treatment.  All study  treatment must be stored in a secure area 
with access limited to the investigator and authorised site staff.  
Mepolizumab will be supplied in a single use prefilled sy ringe contained with in an 
autoinjector and should be stored in a refrigerator at 2 to 8°C with protection from light. 
Each injection device will contain 100 mg mepolizumab as a single 1.0 mL injection of 
the liquid drug product (100 mg/mL).  Maintenance of a temperature log a t the clinical 
dispensing sites (manual or automated) is required.
The investigator or designee must confirm appropriate temperature conditions 
have been maintained during transit for all study  treatment received and any  
discrepancies are reported and reso lved before use of the study  treatment.
Only  the subject or previously  identified caregiver may  administer the study  
treatment.  Whilst on site, all study  treatments must be stored in a secure 
environmentally  controlled and monitored (manual or automated) area in 
accordance with the labelled storage conditions with access limited to the 
investigator and authorised site staff. 
The investigator, institution, or the head of the medical institution (where 
applicable) is responsible for study  treatment accounta bility , reconciliation, and 
record maintenance (i.e. receipt, reconciliation and final disposition records).  
Further guidance and information for final disposition of unused study  treatment 
are provided in the SRM. 
2016N275054_0 4 CONFIDENTIA L
204959
38Under normal conditions of handling an d administration, study  treatment is not 
expected to pose significant safety risks to site staff .  
A Material Safety  Data Sheet (MSDS)/equivalent document describing 
occupational hazards and recommended handling precautions either will be 
provided to the investigator, where this is required by  local laws, or is available 
upon request from GSK.
Subjects will be provided an autoinjector for home use at Visit 3 and asked to 
follow the information on the IFU with regards to the storage and use of the 
device. C ool bags and cold packs will be provided to transport the autoinjector 
from site to home. Subjects will be asked to return the used autoinjector at Visit 4. 
A record of the dispensing of the autoinjector given to the subject at Visit 3 and 
collection of th e autoinjector returned at Visit 4 will be maintained by  the 
Investigator or designee. The Investigator or designee will also inspect the 
returned autoinjector to determine if the dose has been dispensed correctl y.
6.7. Training Session
Training of study  treatm ent, handling and administration techniques by  qualified study  
site personnel will be provided to the study  participants at Visit 2, prior to self -
administration.  The training is designed to be representative of the instruction and 
training materials that will be used in the post -marketing setting.  The training will 
consist of a walk -through of the IFU for the injection devices b y the site personnel.  The 
first injection will then be observed by site personnel and may  includ efeedback to the 
subject as ne eded.
6.8. Compliance with Study  Treatment A dministration
A record of the number of autoinjectors dispensed and returned b y each subject must be 
maintained and reconciled with study  treatment and compliance records.  
6.8.1. Self-Administration at the Clinic
Following the training (see Section 6.7) at Visit 2 (Week 0), the subject (and/or caregiver, 
if applicable) will self
-administer the first dose of study  treatment by  SC inje ction under 
medical supervision of the investigator or designee at the study  site. The 
subject/caregiver will also administer the dose of study  treatment at the clinic under 
medical supervision, but without further training, at Visit 4 (Week 8). Observatio ns about 
the injection will be recorded b y the investigator or designee using a checklist for the 
doses administered in the clinic. Details of the Observer Checklist can be found in the 
SRM. The subject will complete a patient diary  with a visual analogue scale (VAS) 
indicating the pain experience immediatel y following, 1 -and 24-hours after the dose.
The date, time of the dose, person administering the dose (subject/caregiver) and site of 
administration (thigh, abdomen or upper arm [caregiver onl y]) of eac h dose administered 
in the clinic will be recorded on the observer checklist and in the source documents.  
Subjects will be monitored for 1 hour after mepolizumab self -administrations in the clinic 
at Visit 2 and Visit 4.  I n the event of an acute severe reaction (e.g., anaphylaxis) 
2016N275054_0 4 CONFIDENTIA L
204959
39following administration of study  treatment, there are personnel/staff onsite a t the 
treatment facility  who are appropriatel y trained in basic life support to manage the 
subject including administration of medications (e.g., epinephrine), and have access to a 
system that can promptly transport the patient to another facility  for addi tional care if 
appropriate.
6.8.2. Self-Administration Outside the Clinic
The subject (or caregiver) will self- administer the dose of study  treatment outside the 
clinic and without observation during Week 4, up to 24 hours after attending clinic Visit 
3. The subj ect/caregiver will complete a checklist of the steps required to use the 
autoinjector, which will also include the date and time of dose, site of injection, person 
administering the dose (subject/caregiver) and the ease with which the subject/caregiver 
wasable to complete each of the critical steps required to administer the dose from the 
autoinjector. In addition, the subject will complete the patient diary  capturing the pain 
experienced b y the subject immediately following, 1 -and 24- hours after the dose . 
Subjects will be instructed to contact clinical study  staff if they  have concerns or 
questions regarding self -administration. They  will have the option of returning to the 
clinical site for further training or assistance with self- administration.  Requi rement for 
additional training will be documented.
Compliance with the autoinjector will be assessed through reviewing the subject 
completed checklist, inspection of the returned autoinjector and query ing the subject 
during the next site visit (Visit 4) and documented in the source documents.  
For self -administration of mepolizumab outside of the clinic (at home), subjects should 
be instructed to call the investigator and/or go to an Emergency  Department for any  
unusual sy mptoms (e.g. skin rash [hives] or redness, swelling of the face or mouth, 
becoming wheez y, coughing or having difficulty in breathing and/or feeling weak or light 
headed).
6.9. Treatment of Study  Treatment Overdose
The dose of mepolizumab considered to be an overdose has not been defined. There are 
no known antidotes and GSK does not recommend a specific treatment in the event of a 
suspected overdose. The investigator will use clinical judgment in treating the sy mptoms 
of a suspected overdose.
6.10. Treatment after the End of the Study
The investigato r is responsible for ensuring that consideration has been given to the post -
study  care of the subject’s medical condition, whether or not GSK is providing specific 
post-study  treatment.
There are no plans to provide mepolizumab following stud y completion.
2016N275054_0 4 CONFIDENTIA L
204959
406.11. Concomitant Medications and Non -Drug Therapies
6.11.1. Permitted Medications and Non -Drug Therapies
Throughout the stud y, subjects are to be maintained on their baseline standard of care 
asthma treatment.
For subjects previously receiving mepolizumab , additional a sthma medications such as 
theophy llines or anti -leukotrienes will be permitted provided that they  have been taken 
regularl y in the 3 months prior to first dose of mepolizumab treatment (Visit 2, Week 0).
For subjects who have not previously received mepoli zumab, subjects must have a 
well-documented requirement for regular treatment with high dose inhaled corticosteroid 
(ICS) in the 12 months prior to Visit 1 with or without maintenance oral corticosteroids 
(OCS).
Subjects  18 years old:
ICS dose must be ≥880 mcg/day  fluticasone propionate (FP) (ex-
actuator) or equivalent daily .
For ICS/LABA combination preparations, the highest 
strength
approved maintenance dose in the local country  will meet this I CS 
criterion.
Subjects  12 to 17 years old:
ICS dose must be ≥
440 mcg/day FP (ex -actuator) or equivalent dail y.
For ICS/LABA combination preparations, the mid-strength approved 
maintenance dose in the local country  will meet this I CS criterion.
(Subjects will be permitted to be enrolled without continuous high dose ICS providing the 
subject was receiving continuous ICS and the Investigator attests that the subject should 
have been treated with high dose ICS to mitigate the risk of exacerbations bu t financial 
or tolerance issues prevented the use of high-dose ICS. Such subjects should be discussed 
with GSK Medical Monitor prior to enrolment)
Subject not previously  receiving mepolizumab must also be receiving current 
treatment with an additional cont roller medication, besides I CS, for at least 3 
months or a documented failure in the past 12 months of an additional controller 
medication [e.g., LABA, LTRA, or theoph ylline] for at least 3 successive months.  
All concomitant medications taken during the study  will be recorded in the eCRF. In 
addition, all medications taken b y the patient for the treatment of asthma including 
asthma exacerbations in the 12 months prior to Visit 1 must also be recorded in the 
eCRF. The minimum requirement is that the drug n ame and the dates of administration 
are recorded.
2016N275054_0 4 CONFIDENTIA L
204959
416.11.2. Prohibited Medications and Non- Drug Therapies
The following medications ( Table 2) are not allowed prior to screening (Visit 1) 
according to the following schedule, or during the study :
Table 2 Medications not allo wed prior to the Screening Visit 1 and 
throughout the study
MedicationWashout Time
Prior to Screening Visit 1
Omalizumab (Xolair) Within 130 days
Other monoclonal antibodies (other than Xolair or 
mepolizumab) to treat inflammatory disease5 half -lives
Investigational drugs (excluding mepolizumab) 30 days or 5 half -lives whichever is 
longer
Chemotherapy 12 months
Recreational drug use is not allowed during the study .
7. STUDY A SSESSMENTS A ND PROCEDURES
Protocol waivers or exemptions are not allowed with the exception of immediate safety  
concerns. Therefore, adherence to the stud y design requirements, including those 
specified in the Time and Events Table, are essential and required for stud y conduct.
This section lists the procedures and parameters of each planned study assessment.  The 
exact timing of each assessment is listed in the Time and Events Table Section 7.1
2016N275054_0 4 CONFIDENTIA L
204959
427.1. Time and Events Table
Pre-screening
Week - 6 to Week -
5aScreening
Week - 4 to Week -
1Week 0 (Day 
1)Week 4 
(±7 days )Week 8
(±7 days)Week 12
(±7 days)
End of Study/
Early Withdrawalb
Procedures                                           Visit number V0 V1 V2 V3 V4 V5
Informed consent X
Demography/child bearing status assessment X
Medical history X
Asthma and Exacerbation history X
Asthma Therapy history X
Smoking history X
Parasitic screeningc X
Prior needle use / self -administration assessment X
Inclusion/Exclusion criteria X
Training session Xd
Autoinjector self -administration in clinic X X
Autoinjector self -administration outside of clinic Xe, f
Laboratory:
Urine pregnancy test X Xd Xd Xd X
Hematology (including eosinophils)g/ Clinical Chemistry X Xd Xd Xd Xd
Urinalysis X
Immunogenicity Xd Xd
PK Xd Xd Xd Xd
Pharmacogeneticsh X
Physical/Clinical:
Vital signsi X Xd Xd Xd X
12-lead ECG X X
Physical examination X X
Weight X
Concomitant Medication X X X X X X
Asthma Exacerbations X X X X X
Serious Adverse Eventsj,k,l X X X X X X
Adverse Eventsj,k,l X X X X
2016N275054_0 4 CONFIDENTIA L
204959
43Pre-screening
Week - 6 to Week -
5Screening
Week - 4 to Week -
1Week 0 (Day 
1)Week 4
(±7 days)Week 8
(±7 days)Week 12
(±7 days)
End of Study/
Early Withdrawalb
Procedures                                            Visit number V0 V1 V2 V3 V4 V5
Dispense patient diary Xm X X
Return/review patient diary X X Xn
Dispense autoinjector for self -administration outside of clinic X
Return/ inspect autoinjector following self -administration 
outside of clinicX Xn,o
Subject completed pain assessment diary (0, 1 -and 24 -
hours post dose)X Xf X
Autoinjector observer assessment checklist X X
Subject/caregiver completed autoinjector checklist Xf
Assessment of injection success X Xp
Device usability/functionality questionnaire X
Exit InterviewQ (X)
a. Pre-screening Visit can occur on the same day as the Screening Visit but must be completed prior to initiating any Visit 1 proced ures; The Pre -screening Visit can be conducted 
up to a maximum of 2 weeks prior to the Screening Visit.
b. The Early Withdrawal Visit will occur 4 weeks ( 7 days) after last dose of mepolizumab for any subject who withdraws prior to Week 12
c. Parasitic screening is only required in countries with high -risk or for subjects who have visited high -risk countries in the past 6 months. Sites should use local laboratories .
d. Perform prior to mepolizumab administration during the study and prior to restarting pre -study mepolizumab treatment on study completion/early withdrawal.
e. Subjects will be instructed to contact clinical study staff at any time if they have concerns or questions regarding self -administration.  They will have the option of returning to the 
clinical site for further training or assistance with self -administration.  Requirement for additional training or assistance will be documented.
f. Self-administration of mepolizumab using the autoinjector should occur within 24 hours following the clinic visit.
g. Includes measurement of eosinophil levels for pharmacodynamic analysis at Visits 2, 3, 4 and 5
h. Pharmacogenetic sample may be drawn any time after the respective informed consent form is signed and the subject is enrolled .
i. Vital signs include temperature, sitting blood pressure, respiratory rate and pulse.
j. Any SAEs assessed as related to study participation (e.g., study treatment, protocol -mandated procedures, invasive tests, or change in existing therapy) or related to a GSK 
concomitant medication, will be recorded from the time a subject consents to participate in the study up to and including any follow up contact. All other AEs/SAEs are rec orded 
from the start of study treatment until the End of Study / Early Withdrawal visit.
k. Injection site reactions (e.g., induratio n, erythema, edema, rash, pruritus, pain) are to be recorded on both AE and SAE CRF forms.
l. Information on systemic reactions  and events that meet the anaphylaxis criteria is collected on both AE and SAECRF  forms
m. Patient diary should be dispensed prior to administration of injection
n. For any subject who withdraws prior to Week 12, patient diary and study drug for self -administration outside of clinic will be returned at the Early Withdrawal visit (if applicable).
2016N275054_0 4 CONFIDENTIA L
204959
44o. Assessment to be completed at the Early With drawal visit only if the dose of mepolizumab immediately prior to withdrawal was administered outside of the clinic.
p. Includes both the injection outside the clinic from Week 4 and the injection in clinic at Week 8
q. In a subset of subjects only. Completed ov er the telephone after the End of Study/Early Withdrawal Visit
2016N275054_0 4 CONFIDENTIA L
204959
457.2. Screening and Critical Baseline A ssessments
Subjects can perform the Pre- screening Visit (Visit 0) up to 2 weeks prior to or on the 
same day  as the Screening Visit (Visit 1).  A subject number will be assigned at the time 
the informed consent form (I CF) is signed.  During the Pre- screening Visit, study  
designated personnel must provide informed consent (includi ng informed consent for the 
optional pharmacogenetics part of the stud y, as applicable) to study participants.
Once the informed consent document has been signed, pre -screening assessments can be 
conducted. The following demographic parameters will be capt ured: year of birth, sex, 
race and ethnicit y. In addition, Asthma Therap y, Asthma and Exacerbation history  and 
concomitant medications will be assessed. From the pre -screening visit onwards 
concomitant medications, exacerbations and SAEs (considered as rel ated to study  
participation) must be reported.
7.2.1. Critical procedures performed at Screening (Visit 1)
Medical history  including smoking status, history of sinusitis, nasal poly posis, 
aspirin sensitivity , current treatment, duration of asthma, courses of resc ue 
corticosteroids in the past 12 months, history  of previous intubations, asthma 
exacerbation history  in the previous 12 months, asthma triggers and smoking history
Prior experience of needle use including an y history of self -administration using an 
autoi njector device
Therap y history , including use of mepolizumab, omalizumab or previous biologics in 
the past 12 months (see Section 6.11.2). For subjects currentl y receiving 
mepolizumab, data will be collected on whether mepolizumab treatment was 
initiated based on an eosinophil count within 6 weeks of starting treatment or a 
historical measurement collected in the 12 months prior to initiating mepolizumab. 
The blood e osinophil count closest to the initiation of mepolizumab treatment, if 
available, should be recorded.
Cardiovascular medical history /risk factors (as detailed in the eCRF). This 
assessment must include a review of the subject responses to the cardiovascula r 
assessment questions and height, weight, blood pressure, smoking history , medical 
conditions, and family  history  of premature cardiovascular disease
Physical exam (see Section 7.7.4
)
Vital signs (see Section 7.7.5 )
Resting 12- lead ECG (see Section 7.7.6
)
Laboratory  tests (see Section 7.7.7). This should include:
Chemistry
Haematology  with differential count
Urinaly sis
Urine pregnancy  test- for all women of child bearing potential
2016N275054_0 4 CONFIDENTIA L
204959
46Follicle stimulating hormone (FSH) will be assessed to confirm child- bearing 
status (if applicable)
Parasitic screening (onl y in countries with a high -risk or in subjects who have 
visited a high -risk country )
Review of Inclusion/Exclusion criteria
Review of exacerbations, SAEs
Procedures conducted as part of the subject’s routine clinical management [e.g. blood 
eosinophil counts] and obtained prior to signing of informed consent may  be utilised for 
Screening or baseline purposes provided the procedure meets the protocol -defined criteria 
and has bee n performed within the timeframe defined in the Time and Events Schedule.
7.2.2. Critical procedures performed at first treatment Visit (Baseline 
Visit 2)
Vital signs (see Section 7.7.5 )
Laboratory  tests (see Section 7.7.7). This should include
Clinical Chemistry
Haematology  with differential
Blood for baseline immunogenicity
Blood for PK assessment
Urine pregnancy  test for all females of childbearing potential
Review of exacerbations, concomitant medications, AEs, SAEs
Review of Continuation to Treatment criteria (see Section 5.3).
Training of the subject or caregiver as to the correct use of the autoinjector
7.3. Assessment of A utoinjector Use
At Visit 2 (Week 0), and at Visit 4 (Week 8), the investigator or designee will observe, 
using a checkli st based on the autoinjector IFU, the ability  of the subject/caregiver to 
(self) -
administer the injection. The Observer Checklist (see SRM) will be used to 
determine if each step, according to the IFU, was completed easily , with some difficulty  
or not completed/intervention required. Failure to perform one of the critical steps, i.e., 
correct choice of injection site and a full dose administered (determined by  the subject 
pushing the autoinjector all the way  down and holding until either the second click, o
r the 
plunger stops moving and the inspection window is filled with the y ellow indicator or by  
the autoinjector being pushed all the way down and held for a total of 15 seconds) will be 
deemed to be a failure to successfull y administer the injection. In ad dition, the 
investigator or designee will be asked to inspect the autoinjector, following each 
injection, to confirm that the y ellow indicator fills the inspection window and the needle 
guard has locked into place (checked b y pressing the needle guard agai nst a firm surface), 
2016N275054_0 4 CONFIDENTIA L
204959
47as well as noting any additional observations which indicate the full dose has not been 
dispensed.
Any user errors or device malfunctions will be recorded and reported using the 
Autoinjector (Pen) Error/Failure Reporting Form (see SRM).  Malfunction or failure of 
the autoinjector meeting the definition of a Medical Device Incident (see Appendix 5 ), 
will also require a Medical Device Incident form to be comp leted and must be reported as 
described in Section 7.7.3 .
Subjects will complete a patient diary  at Week 0, 4 and 8 recording the pain experienced 
immediately  following, 1 -and 24
-hour after the injection (see SRM). At Week 4, when 
self-administration is performed outside the clinic (within 24 -hours of attending the Visit 
3 clinic visit), the subject/caregiver will also record the date and time of injection, site of 
injection, who administered the injection (subject or caregiver) and complete a checklist 
similar to the Observer Checklist outlining the various steps in the IFU and whether each 
step was completed easily, with some difficult y, or not completed (see SRM). The 
responses on the checklist will be checked b y the Investigator or designee at the next 
clinic visit (Visit 4). Failure to perform one of the critical steps will deemed to be a 
failure to successfull y administer the injection.
All devices utilised as part of the study
 will be returned to the clinic where they  will be 
assessed to confirm that the device has been successfully  actuated.  An y unsuccessful 
injection will undergo a root- cause investigation, following a scripted approach, and 
evaluation t o assess whether the unsuccessful injection was associated with the 
instructions / use of the device or whether it was associated with a device failure using 
the Autoinjector (Pen) Error/Failure Reporting Form, further details of which can be 
found in the SRM. All devices, will be evaluated by  Device Engineering, post -use, to 
assess overall performance and robustness of the device.
7.4. Pain Assessment
Following each injection, any  pain at the injection site will be assessed by  the subject 
using a visual analog scale, in the patient diary , immediately  after injection, 1 hour after 
injection and 24 hours ( 4
hours) after injection. The results will be recorded in the 
patient diary . All measurement timings are detailed in the Time and Events Table 
(Section 7.1) and further details regarding the pain assessment are found in the SRM.
7.5. Device Usability /Functionality  Question
A short survey  will be administered to all subjects at the End of Study /Earl y Withdrawal 
Visit. This survey  (see SRM) will collect quantitative data on patient views of treatment 
and the use of the autoinjector. 
7.6. Exit Interviews
Exit interviews will be con ducted after the End of Study /Earl y Withdrawal Visit over the 
telephone, in a subset of subjects only , to explore subjects’ experience with study  
treatment and device usage. Exit interviews are qualitative interviews conducted with 
study  subjects to captu re subject experiences in drug development on completion of 
2016N275054_0 4 CONFIDENTIA L
204959
48participation in a clinical study .Interview questions are designed to fully  assess a 
subject’s experience with a study  medication and autoinjector and are administered in a 
semi -structured forma t over the telephone by  a trained interviewer. Subject feedback will 
be captured in a data collection sheet as well as being audio -taped for subsequent 
transcription and qualitative anal ysis. The Exit interview technique and questions will be 
described in the SRM.
7.7. Safet y
Planned time points for all safety  assessments are listed in the Time and Events Table 
(Section 7.1).  
7.7.1. Adverse Events (A E) and Ser ious A dverse Events (S AEs)
The definitions of an AE or SAE can be found in Appendix 6.
The following adverse events of special interest will have customized AE and SAE pages 
in the eCRF:
Local injection site reactions
Systemic reactions
In addition, the information whether an event met the diagnostic criteria for anaph ylaxis 
as outlined by  the Second Sy mposium on Anaphylaxis [ Sampson, 2006] and in Appendix 
2will be collected on the AE and SAE CRF pages.
The investigator and their designees are responsible for detec
ting, documenting and 
reporting events that meet the definition of an AE or SAE. 
7.7.1.1. Time period and Frequency  for collecting A E and SA E information
Any SAEs assessed as related to study  participation (e.g., protocol- mandated 
procedures, invasive tests, or ch ange in existing therapy ) or related to a GSK 
product will be recorded from the time a subject consents to participate in the 
study  up to and including any  follow -up contact. 
AEs will be collected from the start of Study  Treatment (Visit 2) until the End of 
Study /Earl y Withdrawal Visit at the timepoints specified in the Time and Events 
Table (Section 7.1).
Medical occurrences that begin prior to the start of study  treatment but after 
obtaining informed consent may  be recorded on the Medical History /Current 
Medical Conditions section of the CRF.
All SAEs will be recorded and reported to GSK within 24 hours, as indicated in 
Appendix 6.
Investigators are not obligated to activel y seek AEs or SAEs in former study 
subjects. However, if the investigator learns of an y SAE, including a death, at an y 
time after a subject has been discharged from the study , and he/she considers the 
event reasonabl y related to the study  treatment or study  participation, the 
investigator must promptly  notify  GSK.
2016N275054_0 4 CONFIDENTIA L
204959
49NOTE: The method of recording, evaluating and assessing causality  of AEs and SAEs 
plus p rocedures for completing and transmitting SAE reports to GSK are provided in 
Appendix 6
7.7.1.2. Method of Detecting AEs and SA Es
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open- ended 
and non-leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrence.  Appropriate questions include:
“How are you feeling?” 
“Have you had an y (other) medical problems since y our last visit/contact?” 
“Have you taken an y new medicines, other than those provided in this study , since 
your last visit/contact?” 
7.7.1.3. Follo w
-up of A Es and SA Es
After the initial AE/SAE report, the investig ator is required to proactivel y follow each 
subject at subsequent visits/contacts.  All SAEs, and non -serious AEs of special interest 
(as defined in Section 4.6.1) will be followed until resolution, until the condition 
stabilizes, until the event is otherwise explained, or until the subject is lost to follow -up 
(as defined in Section 5.5). Further information on follow -up procedures is given in 
Appendix 6
.
7.7.1.4. Cardiovascular and Death Events
7.7.1.4.1. Cardiovascular events
Cardiovascular -related AEs and SAEs that will require the investigator to complete event 
specific pages in the eCRF are listed in Section 12.6.3
, Appendix 6.
Cardiovascular events information should be recorded on the corresponding eCRF pages 
within one week of when the AE/SAE(s) are first reported.  Please refer to Appendix 6
for timelines for reporting AE/SAEs.
7.7.1.4.2. Deaths
In addition, all deaths will require completion of a specific death data collection page in 
the eCRF.  The death data collection page in the eCRF includes questions regarding 
cardiovascular (including sudden cardiac death) and non
-cardiovascular death.
Death information should be recorded on the death eCRF page within one week of when 
the death is first reported.
Please refer to Section 12.6.6 , Appendix 6for timelines for reporting SAEs.
7.7.1.5. Regulatory  Reporting Requirements for SA Es
Prompt notification by  the investigator to GSK of SAEs related to study treatment (even 
for non -interventional post -marketing studies) is essential so that legal obligations and 
2016N275054_0 4 CONFIDENTIA L
204959
50ethical responsibilities towards the safet y of subjects and the safety of a product under 
clinical investigation are met. 
GSK has a legal responsibility  to notify  both the local regulatory  authorit y and other 
regulatory  agencies about the safet y of a product under clinical investigation.  GSK will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the 
regulatory  authority, Institutional Review Board (IRB)/Indepen dent Ethics Committee 
(IEC) and investigators.
Investigator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and GSK policy  and are forwarded 
to investigators as necessary .
An investi gator who receives an investigator safety report describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from GSK will file it with 
the IB and will notify  the I RB/IEC, if appropriate according to local requirements.
7.7.2. Preg nancy
Details of all pregnancies in female subjects will be collected after the start of 
dosing (Visit 2) and until 16 weeks post -last dose.
If a pregnancy  is reported then the investigator should inform GSK within 2 
weeks of learning of the pregnancy  and should follow the procedures outlined in 
Appendix 3 .
7.7.3. Medical Device Incidents (Including Malfunctions)
GSK medical devices are being provided for use in this study .  In order to fulfil 
regulatory  reporting obligations worldwide, the investigator is responsible for the 
detection and documentation of events meeting the definitions of incident or malfunction 
that occur during the study with such devices. 
The definition of a Medical Device Incident can be found in Appendix 5 . 
NOTE: Incidents fulfilling the definition of an AE/SAE will also follow the processes 
outlined in Section 12.6 and Appendix 6of the Protocol. 
7.7.3.1. Time Period for Detecting Medical Device Inci dents
Medical device incidents or malfunctions of the device that result in an incident will 
be detected, documented and reported during all periods of the stud y in which the 
GSK medical devices are available for use. 
If the investigator learns of an y incident at an y time after a subject has been 
discharged from the study, and such incident is reasonably related to a GSK medical 
device provided for the study , the investigator will promptly  notify  GSK.
NOTE: The method of documenting Medical Device Incident s is provided in 
Appendix 5 .
2016N275054_0 4 CONFIDENTIA L
204959
517.7.3.2. Follo w-up of Medical Device Incidents
All medical device incidents involving an AE, will be followed until resolution of 
the event, until the cond ition stabilizes, until the condition is otherwise explained, or 
until the subject is lost to follow -up (as defined in Section 5.5).  This applies to all 
subjects, including those withdrawn prematurel y. 
The investigator is responsible for ensuring that follow- up includes an y supplemental 
investigations as may be indicated to elucidate as completely  as practical the nature 
and/or causality  of the incident.
New or upd ated information will be recorded on the originally  completed form with 
all changes signed and dated by  the investigator.
7.7.3.3. Prompt Reporting of Medical Device Incidents to GSK
Medical device incidents will be reported to GSK within 24 hours once the 
investig ator determines that the event meets the protocol definition of a medical 
device incident.
Facsimile transmission of the "Medical Device Incident Report Form" is the 
preferred method to transmit this information to the Medical Monitor.
The same individual will be the contact for receipt of medical device reports and 
SAEs.
In the absence of facsimile equipment, notification by  telephone is acceptable for 
incidents, with a cop y of the "Medical Device Incident Report Form" sent by 
overnight mail. 
7.7.3.4. Regulatory  Reporting Requirements for Medical Device Incidents
The investigator will promptly  report all incidents occurring with any  GSK medical 
device provided for use in the study  in order for GSK to fulfil the legal responsibility  
to notify  appropriate regulatory  bodies and other entities about certain safety  
information relating to medical devices being used in clinical studies.
The investigator, or responsible person according to local requirements (e.g., the 
head of the medical institution in Japan), will comply with the applicable local 
regulatory  requirements relating to the reporting of incidents to the I RB/IEC.
7.7.4. Physical Exams
A complete ph ysical examination will include, at a minimum, assessment of the 
Cardiovascular, Respiratory , Gastrointestinal and Neurolo gical s ystems. Height 
and weight will also be measured and recorded at Visit 1.
Investigators should pay  special attention to clinical signs related to previous 
serious illnesses.
2016N275054_0 4 CONFIDENTIA L
204959
527.7.5. Vital Signs
As detailed in the Time and Events Schedule Table (Section 7.1), vital signs will 
be measured in semi-supine position after 5 minutes rest and will include systolic 
and diastolic blood pressure and pulse rate.
Vital signs assessments will be taken before measurement of an y ECGs at the 
specified time point.
7.7.6. Electrocardiogram (ECG)
A single 12 -lead ECG will be obtained at each timepoint specified in the Time 
and Events Schedule Table (Section 7.1
) during the study  using an ECG machine 
that automatically  calculates the heart rate and measures PR, QRS, QT, and QTc 
intervals.  
If a routine single ECG demo nstrates a prolonged QT interval, obtain two more 
ECGs over a brief period, and then use the averaged QTc values of the three 
ECGs to determine whether the patient should be discontinued from the study .  
Refer to Section 5.5.3 for QTc withdrawal criteria and additional QTc readings 
that may  be necessary .
ECG measurements will be made after the subject has rested in the supine position 
for 5 minutes.  The ECG should be obtained after the vital signs assessments and 
followed b y other stud y procedures. 
7.7.7. Clinical Safety  Laboratory  Assessments
All protocol required laboratory  assessments, as defined in Table 3, must be conducted in 
accordance with the Laboratory  Manual, and Protocol Time and Events Schedule.
Laboratory  requisition forms must be completed and samples must be clearly  labelled 
with the subject number, protocol number, si
te/centre number, and visit date. Details for 
the preparation and shipment of samples will be provided b y the laboratory and are 
detailed in the laboratory manual. Reference ranges for all safet y parameters will be 
provided to the site by  the laboratory  responsible for the assessments.
If additional non -protocol specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in subject management or are 
considered clinically  significant by  the investigator (e.g., SAE or AE or dose 
modification) the results must be recorded in the CRF.
Refer to the SRM for appropriate processing and handling of samples to avoid duplicate 
and/or additional blood draws.
Haematology , clinical chemistry , urinal ysis and additional parameters to be tested are 
listed in Table 3.
2016N275054_0 4 CONFIDENTIA L
204959
53Table 3 Protocol Required Safety  Laboratory  Assessments
Laboratory 
AssessmentsParameters
Haematology Platelet Count RBC Indices :WBC count with Differential :
RBC Count MCV Neutrophils
Hemoglobin MCH Lymphocytes
Hematocrit Monocytes
Eosinophils
Basophils
Clinical 
Chemistry  1BUN Potassium AST (SGOT) Total and direct 
bilirubin
Creatinine Sodium ALT (SGPT) Total Protein
Glucose Calcium Alkaline phosphatase Albumin
Routine 
Urinaly sisSpecific gravit y
pH, glucose, protein, blood and ketones b y dipstick
Microscopic examination (if blood or protein is abnormal)
Other 
Screening 
TestsFSH and estradiol (as needed in women of non -child bearing 
potential only )
Urine hCG Pregnancy  test (as needed for women of child bearing 
potential) 2
Parasitic screening (onl y required in countries with high -risk or for 
subjects who have visited hig h-risk countries in the past 6 months). 
Sites should use local laboratories.
NOTES :
1.Details of L iver Chemistry  Stopping Criteria and Required Actions and Follow -Up 
Assessments after liver stopping or monitoring event are given in Section 5.5.2 and 
Appendix 4 .
2.Local urine testing will be standard for the protocol unless serum testing is required 
by local regulation or ethics committee.
RBC: Red blood cell; MCV: Mean corpuscular volume; MCH: Mean corpuscular haemoglobin;BUN: Blood urea 
nitrogen; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; FSH: Follicle stimulating h ormone
All laboratory  tests with values that are considered clinically  significantl y abnormal 
during participation in the study  should be repeated until the values return to normal or 
baseline.  If such values do not return to normal within a period judg ed reasonable b y the 
investigator, the etiology  should be identified and the sponsor notified.
7.8. Asthma Exacerbations
At each study  visit the investigator will make an assessment of the occurrence of 
an asthma exacerbation.  Any  asthma exacerbation will be r ecorded on the 
appropriate eCRF page.
2016N275054_0 4 CONFIDENTIA L
204959
54An exacerbation of asthma as defined as:
Worsening of asthma which requires use of sy stem ic corticosteroids1and/or 
hospitalization and/or Emergency  Department (ED) visits.
1For all subjects, i.v. or oral steroid (e.g., prednisone) for at least 3 days or a single 
intramuscular corticos teroiddose is required. For subjects on maintenance systemic 
corticosteroids, at least double the existing maintenance dose for at least 3 days is 
required.
7.9. Pharmacody namic Markers
Blood e osinophil counts will be recorded as part of the standard haematological 
assessments performed at the visits specified in the Time and Events Schedule (Section 
7.1).  
7.10. Pharmacokinetics
Blood samples for anal ysis of mepolizumab plasma concentration will be obtained as per 
the Time and Events table (Section 7.1).  Samples obtained at Visits 2, 3, 4 and 5 should 
be drawn prior to dosing.  The date and exact time of collection for each sample will be 
documented in the eCRF.
Details for collection and processing of samples may  be found in the SRM.
7.11. Immunogenicity
Blood samples will be collected for the determination of anti- mepolizumab antibodies, 
prior to dosing, as detailed in the Time and Events Schedule (Section 7.1
)
Details for sample collection and processing may  be found in the SRM.
7.12. Genetics
Information regarding genetic research is included in Appendix 7 .  IEC/I RB and, where 
required, the applicable regulatory  agency  must approve the genetic assessments before 
these can be conducted at the site.  The approval(s) must be in writing and will clearly  
specify  approval of the geneti c assessments (i.e., approval of Appendix 7 ).  In some 
cases, approval of the genetic assessments can occur after approval is obtained for the 
rest of the stud y.  If so, then the written approval will clearl y indicate approval of the 
genetic assessments is being deferred and the study, except for pharmacogenetics (PGx) 
and genetic assessments, can be initiated.  When genetic assessments will not be 
approved, then the approval f or the rest of the study  will clearl y indicate this and 
therefore, genetic assessments will not be conducted.
2016N275054_0 4 CONFIDENTIA L
204959
558. DATA MANAG EMENT
For this study  subject data will be entered into GSK defined CRFs, transmitted 
electronically  to GSK or designee and combined with data provided from other 
sources in a validated data sy stem.  
Management of clinical data will be performed in accordance with applicable 
GSK standards and data cleaning procedures to ensure the integrit y of the data, 
e.g., removing errors and inconsistencies in the data.
Adverse events and concomitant medications terms will be coded using MedDRA 
(Medical Dictionary  for Regulatory  Activities) and an internal validated 
medication dictionary , GSKDrug.  
CRFs (including queries and audit trails) will be reta ined b y GSK, and copies will 
be sent to the investigator to maintain as the investigator cop y.  Subject initials 
will not be collected or transmitted to GSK according to GSK policy .
9. STATISTICA L CONSIDER ATIONS AND DA TA 
ANALYSES
9.1. Hypotheses
The study  is desig ned to descriptivel y evaluate the mepolizumab liquid drug product in 
autoinjector for self -administration by  subjects with severe eosinophilic asthma. 
No formal statistical h ypothesis testing is planned.  The number and percentage of 
subjects successfull y able to self -administer their mepolizumab dose will be reported
separately  for the group of subjects using labelling that includes a pictogram plus 
standard labelling elements or the group using the standard labelling without the 
pictogram, including 95% confidence intervals (CI ). No comparison between the labels 
will be performed.
9.2. Sample Size Considerations
9.2.1. Sample Size A ssumptions
No formal sample size calculations were performed. Assuming a 30% screen failure rate, 
approximately  225 subjects will be screened in order to enrol 158 subjects (attempting at 
least one self -administration of mepolizumab). Assuming a dropout rate of up to 5% 
during the stud y, 15 8enrolled subjects should provide at least 15
0 subjects with complete 
study  data. Approximately  100 subjects will use autoinjec tors with labelling that includes 
a pictogram plus standard labelling elements and 50 subjects will use the standard 
labelling without the pictogram.
No sample size re -assessment/adjustment is planned.
2016N275054_0 4 CONFIDENTIA L
204959
569.2.2. Sample Size Sensitivity
The estimated precision for th e proportion of subjects successfull y able to self -administer 
their mepolizumab dose is presented below. Sample sizes of both 100 and 50 completed 
subjects are included, corresponding to the number of subjects planned to use the
autoinjectors with labellin g that includes a pictogram plus standard labelling elements 
and the standard labelling without the pictogram respectivel y:-
95% CI
(Exact Method)
Observed Proportion
(%)N=100 N=50
70 60, 79 55, 82
80 71, 87 66, 90
82 73, 89 69, 91
84 75, 91 71, 93
86 78, 92 73, 94
88 80, 94 76, 95
90 82, 95 78, 97
92 85, 96 81, 98
94 87, 98 83, 99
96 90, 99 86, 100
98 93, 100 89, 100
9.3. Data Analysis Considerations
Full details of all pre -specified anal yses will be described in the Reporting and Anal ysis 
Plan (RAP).
9.3.1. Analysis Populations
All Subjects Population
The ‘All Subjects’ population will comprise all enrolled subjects (i.e. attempting at least 
one self -administration of mepolizumab). This population will be used for the evaluation 
of the mepolizumab liqu id drug product in autoinjector and for the summaries relating to 
the safet y and tolerability of mepolizumab.
PK Population:
The PK population will be defined as all enrolled subjects for whom at least one PK 
sample was obtained and anal yzed.  This will be the primary  population for assessing PK.
PD Population:
The PD population is defined as all enrolled subjects who also have a baseline PD 
measurement and at least one post- treatment PD measurement. This will be the primary  
population for assessing PD.
2016N275054_0 4 CONFIDENTIA L
204959
579.3.2. Treatment Comparisons
This is a single arm study. There are no treatment comparisons. All anal yses will be 
descriptive.
9.3.3. Interim A nalysis
No interim anal ysis is planned.
9.4. Key Elements of A nalysis Plan
9.4.1. Analyses to Evaluate A utoinjector
All analy ses to e valuat ethe autoinjector will be reported separatel y for subjects using 
autoinjectors with labelling that includes a pictogram plus standard labelling elements or 
subjects using the standard labelling without the pictogram.
Primary Endpoint
The number and percenta ge of subjects successfully  able to self -administer their observed 
third dose at Week 8 will be summarized together with 95% confidence intervals. The 
denominator for the percentage calculation will be the number of subjects attempting an 
injection at Week 8.
Secondary Endpoints
The following will be summarized, including 95% CI s:-
The number and percentage of subjects successfully  able to self -administer their 
unobserved second dose at Week 4. The denominator for the percentage 
calculation will be the number of subjects attempting an injection at Week 4.
The number and percentage of subjects successfully  able to self -administer their 
observed first dose at Week 0. The denominator for the percentage calculation 
will be the number of subjects attempting an in jection at Week 0.
The number and percentage of subjects successfully  able to self -administer both 
their unobserved second dose at Week 4 and their observed third dose at Week 8. 
The denominator for the percentage calculation will be the number of subjects
attempting an injection at both Week 4 and Week 8.
The number and percentage of subjects successfully  able to self -administer all 
three doses at Week 0, 4 and 8. The denominator for the percentage calculation 
will be the number of subjects attempting all 3 doses at Week 0, 4 and 8.
Data collected on the observer checklist relating to the correct use of the autoinjector and 
any device related issues preventing the full dose being administered will be summarized 
at each visit. 
2016N275054_0 4 CONFIDENTIA L
204959
58The root cause evaluation of e ach unsuccessful injection via the Autoinjector (Pen) 
Error/Failure Reporting Form, including an y observations noted by GSK Device 
Engineering, will be summarized separately  by GSK Device Engineering for inclusion 
into the study  report.
Device usabilit y/functionality  assessed at the end of the study  will be summarized. 
9.4.2. Safety  Analyses
AEs will be coded using the MedDRA coding dictionary  and summarized by  preferred 
term. Separate summaries will be provided for all AEs, I P-related AEs, SAEs, events of 
specia l interest (including s ystemic reactions and local injection site reactions) and for 
AEs leading to permanent discontinuation of study  treatment.  All laboratory parameters 
for clinical chemistry  and hematology  will be summarized and tabulated.
Exacerbatio ns will be summarized and listed.
Each ECG parameter at every  assessed time point will be summarized using summary  
statistics.  Summary  statistics of QT interval corrected for heart rate according to 
Fridericia’s formula (QTcF) and QT interval corrected fo r heart rate according to Bazett’s 
formula (QTcB) as well as change from baseline value will be presented by  visit.
Summary  statistics of pulse rate and sy stolic and diastolic blood pressure will be 
presented b y visit.
Pain VAS scores and categorical pain assessments will be summarized by  visit and time 
post injection (immediately  following, 1- and 24 -hours post injection).
Immunogenicit y will be summarized using appropriate descriptive statistics.
9.4.3. Pharmacody namic Analy ses
Ratio to baseline (Visit 2) in blo od eosinophil count will be summarized by visit, using 
summary  statistics appropriate for log -normal data, overall, by  previous mepolizumab use 
(i.e. not receiving mepolizumab treatment at Visit 1 or receiving 100 mg SC 
mepolizumab administered for the tre atment of severe eosinophilic asthma every  4 weeks 
for at least 12 weeks prior to Visit 1) and by  injection site. Values below the lower limit 
of quantification will be imputed as half the lower limit of quantification .
9.4.4. Pharmacokinetic A nalyses
Pharmacokin etic anal ysis will be the responsibility of the Clinical Pharmacology  
Modeling & Simulation department within GSK. 
PK concentrations will be presented in graphical and/or tabular form and will be 
summarized descriptively overall, by previous mepolizumab u se (i.e. not receiving 
mepolizumab treatment at Visit 1 or receiving 100 mg SC mepolizumab administered for 
the treatment of severe eosinophilic asthma every 4 weeks for at least 12 weeks prior to 
Visit 1) and by  injection site.
2016N275054_0 4 CONFIDENTIA L
204959
5910. STUDY GOVERNANCE CON SIDERAT IONS
10.1. Posting of Information on Publicly  Available Clinical Trial 
Registers
Study  information from this protocol will be posted on publicly  available clinical trial 
registers before enrolment of subjects begins.
10.2. Regulatory  and Ethical Considerations, Includ ing the 
Informed Consent Process
Prior to initiation of a site, GSK will obtain favourable opinion/approval from the 
appropriate regulatory  agency  to conduct the study in accordance with I CH Good Clinical 
Practice (GCP) and applicable country -specific regu latory  requirements.
The study  will be conducted in accordance with all applicable regulatory  requirements, 
and with GSK policy .
The study  will also be conducted in accordance with I nternational Conference on 
Harmonisation (ICH) Good Clinical Practice (GCP), all applicable subject privacy  
requirements, and the guiding principles of the current version of the Declaration of 
Helsinki.  This includes, but is not limited to, the following:
IRB/IEC review and favorable opinion/approval of the study  protocol and 
amendments as applicable
Obtaining signed informed consent
Investigator reporting requirements (e.g. reporting of AEs/SAEs/protocol 
deviations to I RB/IEC)
GSK will provide full details of the above procedures, either verball y, in writing, 
or both.
Signed i nformed consent must be obtained for each subject prior to participation 
in the study
The IEC/I RB, and where applicable the regulatory authority, approve the clinical 
protocol and all optional assessments, including genetic research.  
Optional assessments (including those in a separate protocol and/or under separate 
informed consent) and the clinical protocol should be concurrentl y submitted for 
approval unless regulation requires separate submission.  
Approval of the optional assessments may  occur after approval is granted for the 
clinical protocol where required b y regulatory  authorities.  I n this situation, 
written approval of the clinical protocol should state that approval of optional 
assessments is being deferred and the study , with the exception of the optional 
assessments, can be initiated.
2016N275054_0 4 CONFIDENTIA L
204959
6010.3. Qualit y Control (Study  Monitoring)
In accordance with applicable regulations including GCP, and GSK procedures, 
GSK monitors will contact the site prior to the start of the study  to review with the 
site staff the protocol, study  requirements, and their responsibilities to satisfy  
regulatory , ethical, and GSK requirements.  
When reviewing data collection procedures, the discussion will also include 
identification, agreement and documentation of data items for whic h the eCRF 
will serve as the source document.
GSK will monitor the study  and site activity  to verify  that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accordance with the currently approved protocol and any  
other study  agreements, GCP, and all applicable regulatory  requirements.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents.
10.4. Qualit y Assurance
To ensure compliance with GCP and all applicable regulatory  requirements, GSK 
may conduct a quality  assurance assessment and/or audit of the site records, and 
the regulatory  agencies may  conduct a regulatory inspection at any  time during or 
after c ompletion of the study . 
In the event of an assessment, audit or inspection, the investigator (and institution) 
must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to all 
relevant documents and to allocate their time and the time of their staff to discuss 
the conduct of the stud y, any findings/relevant issues and to implement any 
corrective and/or preventative actions to address any  findings/issues identified.
10.5. Stud y and Site Closure
Upon completion or premature discontinuation of t he study , the GSK monitor will 
conduct site closure activities with the investigator or site staff, as appropriate, in 
accordance with applicable regulations including GCP, and GSK Standard 
Operating Procedures.
GSK reserves the right to temporaril y suspen d or prematurel y discontinue this 
study  at an y time for reasons including, but not limited to, safety  or ethical issues 
or severe non -compliance. For multicenter studies, this can occur at one or more 
or at all sites.  
If GSK determines such action is nee ded, GSK will discuss the reasons for taking 
such action with the investigator or the head of the medical institution (where 
applicable).  When feasible, GSK will provide advance notification to the 
investigator or the head of the medical institution, wher e applicable, of the 
impending action.
2016N275054_0 4 CONFIDENTIA L
204959
61If the study is suspended or prematurely discontinued for safet y reasons, GSK will 
promptly  inform all investigators, heads of the medical institutions (where 
applicable) and/or institution(s) conducting the study . GSK will also promptly  
inform the relevant regulatory authorities of the suspension or premature 
discontinuation of the study  and the reason(s) for the action.  
If required b y applicable regulations, the investigator or the head of the medical 
institution ( where applicable) must inform the I RB/I EC promptl y and provide the 
reason for the suspension or premature discontinuation.
10.6. Records Retention
Following closure of the study , the investigator or the head of the medical 
institution (where applicable) must maintain all site study  records (except for 
those required b y local regulations to be maintained elsewhere), in a safe and 
secure location.  
The records must be maintained to allow eas y and timely  retrieval, when needed 
(e.g., for a GSK audit or regulatory  inspection) and must be available for review 
in conjunction with assessment of the facilit y, supporting s ystems, and relevant 
site staff.  
Where permitted b y local laws/regulations or institutional policy, some or all of 
these records can be maintained in a format other than hard cop y (e.g., microfiche, 
scanned, electronic); however, caution needs to be exercised before such action is 
taken.  
The investigator must ensure that all reproductions are legible and are a true and 
accurate cop y of the original and meet accessibility and retrieval standards, 
including re -generating a hard cop y, if required.  Furthermore, the investigator 
must ensure th ere is an acceptable back -up of these reproductions and that an 
acceptable qualit y control process exists for making these reproductions.
GSK will inform the investigator of the time period for retaining these records to 
comply  with all applicable regulato ry requirements.  The minimum retention time 
will meet the strictest standard applicable to that site for the study, as dictated by 
any institutional requirements or local laws or regulations, GSK 
standards/procedures, and/or institutional requirements.  
The investigator must notify  GSK of any  changes in the archival arrangements, 
including, but not limited to, archival at an off- site facility  or transfer of 
ownership of the records in the event the investigator is no longer associated with 
the site.
10.7. Provision of Study  Results to Investigators, Posting of 
Information on Publically  Available Clinical Trials Registers 
and Publication
Where required b y applicable regulatory  requirements, an investigator signatory  will be 
identified for the approval of the clin ical study  report.  The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
2016N275054_0 4 CONFIDENTIA L
204959
62opportunity  to review the complete study  results at a GSK site or other mutually -
agreeable location.
GSK will als o provide the investigator with the full summary  of the stud y results.  The 
investigator is encouraged to share the summary  results with the study  subjects, as 
appropriate.
The procedures and timing for public disclosure of the results summary  and for 
deve lopment of a manuscript for publication will be in accordance with GSK Policy .
A manuscript will be progressed for publication in the scientific literature if the results 
provide important scientific or medical knowledge.
2016N275054_0 4 CONFIDENTIA L
204959
6311. REFERENCES
Bel EH, Wenzel SE, Tho mpson PJ, Prazma CM, Keene ON, Yancey  SW et al. Oral 
Glucocorticoid -Sparing Effect of Mepolizumab in Eosinophilic Asthma. N Engl J Med
2014;371(13):1189 -1197.
Global Strategy  for Asthma Management and Prevention, Global I nitiative for Asthma 
(GINA) 2015. A vailable from: http://www.ginasthma.org/.
Haldar P, Brightling CE, Hargadon B, Gupta, S, Monteiro W, Sousa A, et al. 
Mepolizumab and exacerbations of refractory  eosinophilic asthma. N Engl J Med. 
2009;360:973-984.
Investigator Brochure (IB) GSK Document Number CM2003/00010/12, Date 05 NOV 
2016.
Nair P, Pizzichini MMM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini, E et al. 
Mepolizumab for prednisone -dependent asthma with sputum eosinophilia. N Engl J Med. 
2009;360:985-993.
National heart, lung and blo od institute (NI H) 2007. Expert panel report 3: Guidelines 
for the diagnosis and management of asthma. National asthma education and prevention 
program. Available at: http://www.nhlbi.nih.gov/health- pro/guidelines/current/asthma -
guidelines/full -report
Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A et al. 
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. N Engl J Med
2014;371(13):1198 -1207.
Pavord ID, Korn S, Howarth P, Bleeker ER, Buhl R, Keene ON et al. Mepolizumab for
severe eosinophilic asthma (DREAM): a multicentre, double -blind, placebo -controlled 
trial. Lancet 2012;380:651
–659.
Sampson HA, Munoz- Furlong A, Campbell RL , Adkinson Jr FN, Bock AS, Branum A et 
al. Second s ymposium on the definition and management of ana phylaxis: summary  
report —Second National I nstitute of Allergy  and Infectious Disease/Food Allergy  and 
Anaph ylaxis Network symposium. J Allergy Clin Immunol 2006;117:391-
397.
2016N275054_04 CONFIDENTIA L
204959
6412. APPENDICES
12.1. Appendix 1: A bbreviations and Trademarks
Abbrev iations
ACQ Asthma Control Questionnaire
ADA Anti- drug antibody
AE Adverse Event
ALT Alanine aminotransferase
AST Aspartate aminotrasferase
BUN Blood urea nitrogen
CI Confidence Interval
CONSORT Consolidated Standard of Reporting Trials
COPD Chronic obstructive pulmonary  disease
CRF Case report form
CS Corticosteroid
Ctrough Trough concentration at the end of the dosing interval
CV Cardiovascular
DNA Deox yribonucleic acid
ECG Electrocardiogram
eCRF Electronic Case Report Form
ED Emergency  Department
EGPA Eosinophilic granulomatosis with poly angiitis
EMEA European Medicines Agency
EU European Union
FAAN Food Allergy  and Anaphylaxis Network
FDA Food and Drug Administration
FEV 1 Forced expiratory  volume in 1 second
FP Fluticasone Propionate
FRP Females of Reproductive Potential
FSH Follicle stimulating hormone
G Gauge
g gram
GCP Good Clinical Practice
GCSP Global Clinical Safety  and Pharmacovigilance
GINA Global Initiative for Asthma
GSK GlaxoSmithKline
hCG Human chorionic gonadotropin
HES Hypereosinophilic Sy ndrome
hIL Human interleukin
HIV Human immunodeficiency virus
HRT Hormone replacement therap y
IB Investigator’s Brochure
ICF Informed consent form
ICH International Conference on Harmonisation
2016N275054_04 CONFIDENTIA L
204959
65ICS Inhaled corticosteroids
IEC Independent Ethics Committee
IFU Instructions for Use
IgG Immunoglobulin
IL Interleukin
IM Intramuscular
IP Investigational Product
IRB Institutional Review Board
IV Intravenousl y
kg Kilogram
LABA Lon-acting beta -2-agonist
LTRA Leukotriene receptor antagonist
mAb Monoclonal antibody
mcg Microgram
MCH Mean corpuscular hemoglobin
MCV Mean corpuscular volume
MedDRA Medical Dictionary  for Regulatory  Activities
mg Milligram
mL Milliliter
mm Hg Milliliter of mercury
MSDS Material Safet y Data Sheet
N/A Not applicable
NAb Neutralising antibody
NIAI D National Institute of Allergy  and Infectious Disease
NIH National Heart Lung and Blood Institute
OCS Oral corticosteroids
PCSA Placebo- controlled severe asthma
PD Pharmacod ynamic
PEF Peak expiratory  flow
PGx Pharmacogenetics
PK Pharmacokinetic
QTc QI interval corrected for heart rate
QTcB QT interval corrected for heart rate b y Bazett’s formula
QTcF QTinterval corrected for heart rate b y Fridericia’s formula
R&D Research & Development
RAP Reporting and Anal ysis plan
RBC Red blood cell
RNA Ribonucleic acid
SAE Serious Adverse Event
SC Subcutaneous(l y)
SGRQ St George’s Respiratory  Questionnaire 
SRM Study  reference manual
UK United Kingdom
ULN Upper limit of normal
US United States
V Visit
2016N275054_04 CONFIDENTIA L
204959
66VAS Visual Analogue Scale
WFI Water for injection
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by the 
GlaxoSmithKline group of companies
NUCALA SAS
Xolair (omalizumab)
Ypsomed AG
2016N275054_04 CONFIDENTIA L
204959
6712.2. Appendix 2: Anaphy laxis Criteria
Joint NI AID/FAAN Second Sy mposium on Anaphy laxis [ Sampson, 2006]. The criteria 
do not make a distinction based on underl ying mechanism. These criteria are summarized 
as follows:
1) Acute onset of an illness (minutes to several hours) with involvement of the skin, 
mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen lips -
tongue -
uvula), and at least one of the following:
a)Respiratory  compromise (e.g., dy spnea, wheeze- bronchospasm, stridor, 
reduced peak expiratory  flow [PEF], hy poxe mia) 
b)Reduced blood pressure (BP) or associated s ymptoms of end -organ 
dysfunction (e.g., hy potonia [collapse], sy ncope, incontinence)
2) Two or more of the following that occur rapidly  after exposure to a likel y allergen 
for that patient (minutes to several h ours):
a)Involvement of the skin -mucosal tissue (e.g., generalized hives, itch -flush, 
swollen lips -tongue -uvula)
b)Respiratory  compromise (e.g., dy spnea, wheeze- bronchospasm, stridor, 
reduced PEF, h ypoxemia)
c)Reduced BP or associated sy mptoms (e.g., hy potonia [collapse], sy ncope, 
incontinence)
d)Persistent gastrointestinal sy mptoms (e.g., crampy abdominal pain, vomiting)
3)Reduced BP after exposure to known allergen for that patient (minutes to several 
hours):
a)Infants and children: low sy stolic BP (age specific) or greater than 30% 
decrease in s ystolic BP
b)Adults: sy stolic BP of less than 90 mm Hg or greater than 30% decrease from 
that person’s baseline
References
Sampson HA, Munoz- Furlong A, Campbell RL , Adkinson Jr FN, Bock AS, Branum A et 
al. Second s ymposium on the definition and management of anaph ylaxis: summary  
report —Second National I nstitute of Allergy  and Infectious Disease/Food Allergy  and 
Anaph ylaxis Network symposium. J Allergy Clin Immunol 2006;117:391-
397.
2016N275054_04 CONFIDENTIA L
204959
6812.3. Appendix 3 : Modified List of Highly  Effective Methods for 
Avoiding Pregnancy  in FRP and Collection of Pregnancy  
Information
12.3.1. Definition of post menopausal female
Post menopausal female is defined as:
Females 60 years of age or older
Menopause is the phase associated with complete cessation of menstrua l cycles and 
implies the loss of reproductive potential by  ovarian failure. This t ypicall y occurs 
around 50 years of age, although it may occur earlier or later. A practical definition 
accepts menopause after 1 y ear without menses with an appropriate clini cal profile, 
e.g., age appropriate, >45 y ears, in the absence of hormone replacement therapy  
(HRT) or medical suppression of the menstrual cycle (e.g., leuprolide treatment).
In questionable cases for women < 60 years of age, a blood sample with simultaneous 
follicle stimulating hormone and estradiol falling into the central laboratory’s 
postmenopausal reference range is confirmatory  (these levels need to be adjusted for 
specific laboratories/assays) [ Kronenberg , 2008; Strauss, 2004].
Females under 60 years of age, who are on HRT and wish to continue, and whose 
menopausal status is in doubt, are required to use a highl y effective method to avoid 
pregnancy , as outlined in the protocol. Otherwise, they  must discontinue HRT to 
allow confirmation of post
-menopausal status prior to study enrolment. For most 
forms of HRT, at least 2 to 4 weeks will elapse between the cessation of therap y and 
the blood draw; this interval depends on the t ype and dosage of HRT. Following 
confirmation of their post- menopausal status, they can resume use of HRT during the 
study  without use of a highl y effective method to avoid pregnancy . If laboratory  
values for FSH and estradiol are drawn and the results do not confirm menopause on 
a potential subject that otherwise met the specifications for being post -menopausal 
defined above without question, the subject may still enrol in the study  as a FNRP if 
approved b y the GSK Medical Monitor and the safety ph ysician.
12.3.2. Modified List of Highly Effective Methods for Avoiding Pregnancy  
in Females of Reproductive Potential (FRP)
The list does not apply  to FRP with same sex pa rtners or for subjects who are and will 
continue to be abstinent from penile-vaginal intercourse on a long term and persistent 
basis, when this is their preferred and usual lifest yle. Periodic abstinence (e.g. calendar, 
ovulation, sy mptothermal, post -ovul ation methods) and withdrawal are not acceptable 
methods of contraception.
1.Contraceptive subdermal implant
2.Intrauterine device or intrauterine s ystem
3. Combined estrogen and progestogen oral contraceptive [ Hatcher , 2011])
4.Injectable progestogen [ Hatcher , 2011]
2016N275054_04 CONFIDENTIA L
204959
695.Contraceptive vaginal ring [ Hatcher , 2011]
6.Percutaneous contraceptive patches [ Hatcher , 2011]
7. Male partner sterilization with documentation of azoospermia prior to the female 
subject's entry  into the study , and this male is the sole partner for that subject 
[Hatcher , 2011]. The documentation on male sterility  can come from the site 
personnel’s: review of subject’s medical records, medical examination and/or semen 
analysis, or medical history  interview provided b y her or her partner.
These allowed methods of contraception are only  effective when used consistently , 
correctly  and in accordance with the product label. The investigator is responsible for 
ensuring that subjects understand how to prope rly use these methods of contraception.
12.3.3. Collection of Pregnancy  Information
Investigator will collect pregnancy  information on any  female subject, who becomes 
pregnant while participating in this study
Information will be recorded on the appropriate form a nd submitted to GSK within 2 
weeks of learning of a subject's pregnancy .
Subject will be followed to determine the outcome of the pregnancy . The 
investigator will collect follow up information on mother and infant, which will be 
forwarded to GSK.  Generall y, follow-up will not be required for longer than 6 to 8 
weeks bey ond the estimated delivery  date. 
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy will be reported as an AE or 
SAE.
A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such.  
Any SAE occurring as a r esult of a post -study  pregnancy  which is considered 
reasonabl y related to the study  treatment by  the investigator, will be reported to GSK 
as described in Appendix 6. While th e investigator is not obligated to actively  seek 
this information in former study  participants, he or she may  learn of an SAE through 
spontaneous reporting.
Any female subject who becomes pregnant while participating will be withdrawn 
from the study.
2016N275054_04 CONFIDENTIA L
204959
7012.3.4. References
Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Stewart F, Kowal D, Policar MS, 
editors. Contraceptive Technology . 20thedition. Atlanta, Georgia: Ardent Media, Inc., 
2011: 50. Table 3-2.
Kronenberg HM, Melmed S, Polonsky  KS, Larsen PR, editor s.Williams Textbook of 
Endocrinology , 11th edition. Philadelphia: Saunders, 2008.
Strauss JF, Barbieri RL, editors. Yen and Jaffe’s Reproductive Endocrinology . 5th 
edition, Philadelphia, Elsevier/Saunders, 2004.
2016N275054_04 CONFIDENTIA L
204959
7112.4. Appendix 4: Liver Safety  Required A ction s and Follow up 
Assessments
12.4.1. Liver chemistry  stopping criteria and required follow up 
assessments
Liver Chemistry Stopping Criteria - Liver Stopping Event
ALT- absolute ALT  8xULN
ALT Increase ALT  5xULN but <8xULN  persists for 2 weeks
ALT  3xULN but <5xULN  persists for 4 weeks
Bilirubin1, 2ALT  3xULN andbilirubin 2xULN (>35% direct bilirubin) 
INR2ALT  3xULN andINR>1.5, if INR measured
Cannot 
MonitorALT  5xULN but <8xULN and cannot be monitored weekly for  2 weeks
ALT  3xULN but <5xULN and cannot be monitored weekly for 4 weeks
Symptomatic3ALT   3xULN associated with symptoms (new or worsening) believed to be 
related to  liver injury or hypersensitivity
Required Actions and Follow up Assessments following ANY Liver Stopping Event
Actions Follow Up Assessments
Immediately discontinue study treatment
Report the event to GSK within 24 hours
Complete the liver event CRF and complete 
an SAE data collection tool if the event also 
meets the criteria for an SAE2
Perform liver event follow up assessments 
Monitor the subject until liver chemistries 
resolve , stabilize, or return to within baseline 
(see MONITORING below)
Do not restart/rechallenge subject with 
study treatment.  Permanently discontinue 
study treatmen t and may continue subject in 
the study for any protocol specified follow up 
assessmentsViral hepatitis serology4
Only in those with underlying chronic 
hepatit is B at study entry (identified by 
positive hepatitis B surface antigen) 
quantitative hepatitis B DNA and hepatitis 
delta antibody5.
Blood sample for pharmacokinetic (PK) 
analysis, obtained within 4 weeks after last 
dose6
Serum creatine phosphokinase (CPK) and 
lactate dehydrogenase (LDH).
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia. Note: 
the mechanism of action of mepolizumab 
leads to lowering of eosinophils.
2016N275054_04 CONFIDENTIA L
204959
72MONITORING:
For bilirubin or INR criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments within  24 
hrs
Monitor subjects twice weekly until liver 
chemistries resolve, stabilize or return to 
within baseline
A specialist or hepatology consultation is 
recommended
For All other criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments within  24-
72 hrs 
Monitor subjects weekly until liver 
chemistries resolve, stabilize or return to 
within baselineRecord the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form
Record use of concomitant medications on 
the concomitant medications report form
including acetaminophen, herbal 
remedies, other over the counter 
medications .
Record alcohol use on the liver event 
alcohol intake case report form
For bilirubin or INR criteria:
Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti- liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG or gamma 
globulins).
Serum acetaminophen adduct HPLC 
assay (quantifies potential acetaminophen 
contribution to liver injury in subjects with 
definite or likely acetaminophen use in the 
preceding week [ James , 2009]). NOTE: 
not required in China
Liver imaging (ultrasound, magnetic 
resonance, or computerised tomography) 
and /or liver biopsy to evaluate liver 
disease; complete Liver Imaging and/or 
Liver Biopsy CRF forms.
1. Serum bilirubi n fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that subject if ALT 3xULN andbilirubin 2xULN. 
Additionally, if serum bilirubin fractionation te sting is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury. 
2. All events of ALT 3xULN andbilirubin  2xULN (>35% direct bilirubin) or ALT 3xULN andINR> 1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR measurement is not required and the threshold value stated 
will not apply to subjects receiving anticoagulants
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosino philia)   
4. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody;  Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody o r monospot testing);  Hepatitis E IgM antibody 
5. If hepatitis delta antibody assay cannot be performed,, it can be replaced with a PCR of hepatitis D RNA virus 
(where needed) [ Le Gal , 2005].
6. PK sample may not be required for subjects known to be receiving placebo or non -GSK comparator treatments.  
Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to 
blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the subject’s best 
2016N275054_04 CONFIDENTIA L
204959
73approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected in 
the time period indicated above, do not obtain a PK sample. I nstructions for sample handling and shipping are in 
the SRM.
12.4.2. Liver chemistry  increased monitoring criteria with continued 
therapy
Liver Chemistry Increased Monitoring Criteria – Liver Monitoring Event
Criteria Actions
ALT  5xULN and <8xULN andbilirubin 
<2xULN without symptoms believed to 
be related to liver injury or 
hypersensitivity, andwho can be 
monitored weekly for 2 weeks.
OR
ALT  3xULN and <5xULN andbilirubin 
<2xULN without symptoms believed to 
be related to liver injury or 
hypersensit ivity, andwho can be 
monitored weekly for 4 weeks.Notify the GSK medical monitor within 24 hours of 
learning of the abnormality to discuss subject 
safety. 
Subject can continue study treatment
Subject must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabilise or return to 
within baseline 
If at any time subject meets the liver chemistry 
stopping criteria, proceed as described above
If ALT decreases from ALT 5xULN and <8xULN to 
≥3xULN but <5xULN, continue to monitor liver 
chemistries weekly. 
If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor subjects twice monthly 
until liver chemistries normalize or return to within 
baseline.
References
James L P, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmacokinetics of Acetaminophen -Adduct in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779 -1784.
Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Dény  P, Gault E.  Quantification 
of Hepatitis Delta Virus RNA in Serum by  Consensus Real -Time PCR I ndicates 
Different Patterns of Virological Response to Interferon Therap y in Chronically  Infected 
Patients.  J Clin Microbiol. 2005;43(5):2363–2369. 
2016N275054_04 CONFIDENTIA L
204959
7412.5. Appendix 5: Definition of and Procedures for Documenting 
Medical Device Incidents
12.5.1. Definitions of a Medical Device Incident
The detection and documentation procedures described in this protocol apply  to all GSK 
medical devices provided for use in the stud y (see Section 6.2 for the list of GSK medical 
devices).
Medical Device Incident Definition:
Incident –Any malfunction or deterioration in the characteristics and/or performance 
of a device, as well as any  inadequacy  in the labeling or the instructions for use 
which, direc tly or indirectly , might lead to or might have led to the death of a 
patient/user/other persons or to a serious deterioration in their state of health.
Not all incidents lead to death or serious deterioration in health.  The non -occurrence 
of such a result might have been due to other fortunate circumstances or to the 
intervention of health care personnel.
It is sufficient that:
an incident associated with a device happened and
the incident was such that, if it occurred again, might lead to death or a serio us 
deterioration in health.
A serious deterioration in state of health can include:
life-threatening illness
permanent impairment of body  function or permanent damage to a bod y 
structure
a condition necessitating medical or surgical intervention to prevent one of the 
above 
fetal distress, fetal death or an y congenital abnormality  or birth defects
Examples of incidents
a patient, user, care giver or professional is injured as a result of a medical device 
failure or its misuse
a patient’s treatment is interrupted or compromised by  a medical device failure
misdiagnosis due to medical device failure leads to inappropriate treatment
a patient’s health deteriorates due to medical device failure
2016N275054_04 CONFIDENTIA L
204959
7512.5.2. Documenting Medical Device Incidents
Medical Device Incident Do cumenting:
Any medical device incident occurring during the study  will be documented in the 
subject’s medical records, in accordance with the investigator’s normal clinical 
practice, and on the appropriate form.
For incidents fulfilling the definition of a n AE or an SAE, the appropriate AE/SAE 
CRF page will be completed as described in Appendix 6.
The form will be completed as thoroughl y as possible and signed b y the investiga tor 
before transmittal to GSK.
It is very  important that the investigator provides his/her assessment of causality  to 
the medical device provided by  GSK at the time of the initial report, and describes 
any corrective or remedial actions taken to prevent re currence of the incident.
A remedial action is an y action other than routine maintenance or servicing of a 
device where such action is necessary to prevent recurrence of an incident. This 
includes an y amendment to the design to prevent recurrence.
2016N275054_04 CONFIDENTIA L
204959
7612.6. Appendix 6: Definition of and Procedures for Recording, 
Evaluating, Follow -Up and Reporting of A dverse Events
12.6.1. Definition of A dverse Events
Adverse Event Definition:
An AE is an y untoward medical occurrence in a patient or clinical investigation 
subject, temporall y associated with the use of a medicinal product, whether or not 
considered related to the medicinal product.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a medicinal product.
Events meeting AE definition include:
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (e.g., ECGs, radiological scans, vital signs 
measurements), including those that worsen from baseline, and felt to be clinically  
significant in the medical and scientific judgement of the investigator.
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y treatment administration even 
though it may  have been present prior to the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected intera ction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE unless this is an intentional overdose taken with possible suicidal/self -
harmi ng intent.  This should be reported regardless of sequelae).
The signs and symptoms and/or clinical sequelae resulting from lack of efficacy  will 
be reported if they  fulfil the definition of an AE or SAE.  Also, "lack of efficacy " or 
"failure of expected pharmacological action" also constitutes an AE or SAE.
Events NOT meeting definition of an AE include:
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  the 
investigator to be more severe than expected for the subject’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s
condition.
2016N275054_04 CONFIDENTIA L
204959
77Medical or surgical procedure (e.g., endoscop y, appendectom y): the condition that 
leads to the procedure is an AE.
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
Anticipated day-to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
12.6.2. Definition of Serious A dverse Events
If an event is not an AE per definition above, then it cannot be an SAE even if seri ous 
conditions are met (e.g., hospitalization for signs/sy mptoms of the disease under study , 
death due to progression of disease, etc).
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, 
at any dose:
a.Results in death
b.Is life -threatening
NOTE:
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
subject was at risk of death at the time of the event.  I t does not refer to an event, which 
hypothetically  might have caused death, if it wer e more severe.
c.Requires hospitalization or prolongation of existing hospitalization
NOTE:
In general, hospitalization signifies that the subject has been detained (usually  
involving at least an overnight stay ) at the hospital or emergency  ward for 
observa tion and/or treatment that would not have been appropriate in the phy sician’s 
office or out -patient setting.  Complications that occur during hospitalization are 
AEs.  If a complication prolongs hospitalization or fulfills any  other serious criteria, 
the e vent is serious.  When in doubt as to whether “hospitalization” occurred or was 
necessary , the AE should be considered serious.
Hospitalization for elective treatment of a pre-existing condition that did not worsen 
from baseline is not considered an AE.
d.Results in disability/incapacity
NOTE:
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
2016N275054_04 CONFIDENTIA L
204959
78and accidental trauma (e.g. sprained ankle) which may  interfere or prevent every day 
life functions but do not constitute a substantial disruption
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospitalization but may  jeopardize 
the subject or may  require medical or surgical intervention to prevent one of the 
other outcomes listed in the above definition.  These should als o be considered 
serious.
Examples of such events are invasive or malignant cancers, intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalization, or development of drug dependency  
or drug abuse
g. Is associated with liver injury andimpaired liver function defined as:
ALT 3xULN and total bilirubin*2xUL N (>35% direct), or
ALT 3xULN and INR**>1.5.
* Serum bilirubin fractionation should be performed if testing is available; if unavailable, 
measure urinary  bilirubin via dipstick.  I f fractionation is unavailable and ALT 3xULN 
and total bilirubin  2xULN, then the event is still to be reported as an SA E.
** INR testing not required per protocol and the threshold value does not apply  to 
subjects receiving anticoagulants.  If INR measurement is obtained, the value is to be 
recorded on the SAE form.
12.6.3. Definition of Cardiovascular Events
Cardiovascular Events (CV) Definition:
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
Cerebro vascular events/stroke and transient ischemic attack
Peripheral arterial thromboembolism
2016N275054_04 CONFIDENTIA L
204959
79Deep venous thrombosis/pulmonary  embolism
Revascularization
12.6.4. Recording of A Es and SA Es
AEs and SAE Recording:
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e.g., hospital progress notes, laboratory, and diagnostics reports) 
relative to the event.
The investigator will then record all relevant information regarding an AE/SAE in 
the CRF
It is notacceptable for the inve stigator to send photocopies of the subject’s medical 
records to GSK in lieu of completion of the GSK, AE/SAE CRF page.
There may  be instances when copies of medical records for certain cases are 
requested b y GSK.  In this instance, all subject identifiers, with the exception of the 
subject number, will be blinded on the copies of the medical records prior to 
submission of to GSK.
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical i nformation.  In such cases, the diagnosis will be 
documented as the AE/SAE and not the individual signs/sy mptoms.
12.6.5. Evaluating AEs and SA Es
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during t he stud y and will assign it to one of the following categories:
Mild:  An event that is easily  tolerated by  the subject, causing minimal discomfort 
and not interfering with every day activities.
Moderate:  An event that is sufficiently  discomforting to interfere with normal 
every day activities
Severe:  An event that prevents normal every day activities. -an AE that is assessed 
as severe will not be confused with an SAE. Severity  is a category  utilized for rating 
the intensity  of an event; and both AEs an d SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least one of the pre -defined 
outcomes as described in the definition of an SAE.
2016N275054_04 CONFIDENTIA L
204959
80Assessment of Causality
The investigator is obligated to assess the relationship between study  treatment and 
the occurrence of each AE/SAE.
A "reasonable possibility " is meant to convey that there are facts/evidence or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled 
out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as natural history  of the underly ing diseases, concomitant 
therap y, other risk factors, and the temporal relationship of the event to the study  
treatment will be considered and investigated.
The investigator will also consult the I nvestigator Brochure (IB) and/or Product 
Information, for marketed products, in the determination of his/her assessment.
For each AE/SAE the investigator must document in the medical notes that he/she 
has reviewed t he AE/SAE and has provided an assessment of causality .
There may  be situations when an SAE has occurred and the investigator has minimal 
information to include in the initial report to GSK.  However, it is very important 
that the investigator always make an assessment of causality for every event 
prior to the initial transmission of the SAE data to GSK.
The investigator may  change his/her opinion of causality  in light of follow -up 
information, amending the SAE data collection tool accordingl y.
The causality assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -up of A Es and SA Es
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as may  be indicated or as requested b y GSK to 
elucidate as fully  as possible the nature and/or causality  of the AE or SAE.
The investigator is obligated to assist.  This may  include additional laboratory  tests 
or investigations, histopathological examinations or consultation with other health 
care professionals.
If a subject dies during participation in the study  or during a recognized follow -up 
period, the investigator will provide GSK with a copy  of any  post -mortem findings, 
including histopathology .
New or updated informat ion will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to GSK within the designated 
reporting time frames.
2016N275054_04 CONFIDENTIA L
204959
8112.6.6. Reporting of SA Es to GSK
SAE reporting to GSK via electronic data collection tool
Primary  mechanism for reporting SAEs to GSK will be the electronic data collection 
tool
If the electronic s ystem is unavailable for greater than 24 hours, the site will use the 
paper SAE data collection tool and fax it to the Medical Monitor
Site will enter the se rious adverse event data into the electronic s ystem as soon as it 
becomes available.
The investigator will be required to confirm review of the SAE causality  by ticking 
the ‘reviewed’ box at the bottom of the eCRF page within 72 hours of submission of 
the SAE.
After the stud y is completed at a given site, the electronic data collection tool (e.g., 
InForm s ystem) will be taken off- line to prevent the entry  of new data or changes to 
existing data
If a site receives a report of a new SAE from a study  subject o r receives updated data 
on a previousl y reported SAE after the electronic data collection tool has been taken 
off-line, the site can report this information on a paper SAE form or to the Medical 
Monitor by  telephone.
Contacts for SAE receipt can be found a t the beginning of this protocol on the 
Sponsor/Medical Monitor Contact Information page.
SAE reporting to GSK via paper CRF
Facsimile transmission of the SAE paper CRF is the preferred method to transmit 
this information to the Medical Monitor
In rare circumstances and in the absence of facsimile equipment, notification by  
telephone is acceptable, with a cop y of the SAE data collection tool sent by 
overnight mail
Initial notification via the telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE receipt can be found at this beginning of the protocol on the 
Sponsor/Medical Monitor Contact Information page.
2016N275054_04 CONFIDENTIA L
204959
8212.7. Appendix 7: Genetic Research
Genetics –Background
Naturall y occurring genetic variation may  contribute to inter -individual variability in 
response to medicines, as well as an individual's risk of developing specific diseases. 
Genetic factors associated with disease characteristics may  also be a ssociated with 
response to therap y, and could help to explain some clinical study outcomes. For 
example, genetic variants associated with age- related macular degeneration (AMD) are 
reported to account for much of the risk for the condition [ Gorin , 2012] with certain 
variants reported to influence treatment response [ Chen, 2012]. Thus, knowledge of the 
genetic etiology  of disease may  better inform understanding of disease and the 
development of medicines. Additionally , genetic variability  may  impact the 
pharmacokinetics (absorption, distribution, metabolism, and elimination), or 
pharmacod ynamics (rela tionship between concentration and pharmacologic effects or the 
time course of pharmacologic effects) of a specific medicine and/or clinical outcomes 
(efficacy  and/or safet y) observed in a clinical study.
Genetic Research Objectives and A nalyses
The object ives of the genetic research are to investigate the relationship between genetic 
variants and: 
Response to medicine, including mepolizumab or any  concomitant medicines;
Asthma susceptibility , severity , and progression and related conditions
Genetic data may be generated while the study  is underway  or following completion of 
the study .  Genetic evaluations may  include focused candidate gene approaches and/or 
examination of a large number of genetic variants throughout the genome (whole genome 
analyses). Ge netic anal yses will utilize data collected in the study  and will be limited to 
understanding the objectives highlighted above.  Analy ses may  be performed using data 
from multiple clinical studies to investigate these research objectives.
Appropriate descri ptive and/or statistical analy sis methods will be used. A detailed 
description of an y planned anal yses will be documented in a Reporting and Analy sis Plan 
(RAP) prior to initiation of the anal ysis. Planned analy ses and results of genetic 
investigations wil l be reported either as part of the clinical RAP and study  report, or in a 
separate genetics RAP and report, as appropriate.
Study Population
Any subject who is enrolled in the study  can participate in genetic research.  Any  subject 
who has received an allogeneic bone marrow transplant must be excluded from the 
genetic research.
Study Assessments and Procedures
A key  component of successful genetic research is the collection of samples during 
clinical studies. Collection of samples, even when no a priori hypothesis has been 
2016N275054_04 CONFIDENTIA L
204959
83identified, may  enable future genetic anal yses to be conducted to help understand 
variability  in disease and medicine response.  
A 2 ml blood sample will be taken for Deox yribonucleic acid (DNA) extraction. 
A blood sample is collected at the baseline visit, after the subject has been 
enrolled and provided informed consent for genetic research. Instructions for 
collection and shipping of the genetic sample are described in the laboratory 
manual. The DNA from the blood sample may undergo quality  control analy ses to 
confirm the integrit y of the sample. If there are concerns regarding the quality  of 
the sample, then the sample may  be destroy ed. The blood sample is taken on a 
single occasion unless a duplicate sample is required due to an in abilit y to utilize 
the original sample.  
The genetic sample is labelled (or “coded”) with the same stud y specific number used to 
label other samples and data in the study.   This number can be traced or linked back to 
the subject by  the investigator or site staff. Coded samples do not carry  personal 
identifiers (such as name or social security  number). 
Samples will be stored securel y and may be kept for up to 15 years after the last subject 
completes the study , or GSK may  destroy  the samples sooner.  GSK or those working 
with GSK (for example, other researchers) will only use samples collected from the study  
for the purpose stated in this protocol and in the informed consent form.  Samples may  be 
used as part of the development of a companion diagnostic to support the GSK medicinal 
product.
Subjects can request their sample to be destro yed at any  time.
Informed Consent
Subjects who do not wish to participate in the genetic research may  still participate in the 
study .  Genetic informed consent must be obtained prior to any  blood being taken.
Subject Withdrawal from Study
If a subject who has consented to participate in genetic research withdraws from the 
clinical study  for any  reason other than being lost to follow -
up, the subject will be given a 
choice of on e of the following options concerning the genetic sample, if already  
collected:
Continue to participate in the genetic research in which case the genetic DNA 
sample is retained
Discontinue participation in the genetic research and destroy  the genetic DNA 
sample 
If a subject withdraws consent for genetic research or requests sample destruction for an y 
reason, the investigator must complete the appropriate documentation to request sample 
destruction within the timeframe specified b y GSK and maintain the docu mentation in 
the site study  records . 
2016N275054_04 CONFIDENTIA L
204959
84Genoty pe data may  be generated during the study  or after completion of the study  and 
may be anal yzed during the study  or stored for future anal ysis. 
If a subject withdraws consent for genetic research and genot ype data has not been 
analyzed, it will not be analy zed or used for future research.  
Genetic data that has been anal yzed at the time of withdrawn consent will 
continue to be stored and used, as appropriate. 
Screen Failures
If a sample for genetic research has been collected and it is determined that the subject 
does not meet the entry  criteria for participation in the study , then the investigator should 
instruct the subject that their genetic sample will be destro yed. No forms are required to 
complete this process as it will be completed as part of the consent and sample 
reconciliation process.  In this instance a sample destruction form will not be available to 
include in the site files.
Provis ion of Study Results and Confidentiality  of Subject’s Genetic Data
GSK may  summarize the genetic research results in the clinical study  report, or 
separately  and may  publish the results in scientific journals. 
GSK may  share genetic research data with othe r scientists to further scientific 
understanding in alignment with the informed consent. GSK does not inform the subject, 
family  members, insurers, or employ ers of individual genoty ping results that are not 
known to be relevant to the subject’s medical car e at the time of the study , unless 
required b y law. This is due to the fact that the information generated from genetic 
studies is generall y preliminary in nature, and therefore the significance and scientific 
validity  of the results are undetermined.  Fur ther, data generated in a research laboratory  
may not meet regulatory  requirements for inclusion in clinical care.
References
Chen H, Yu KD, Xu GZ. Association between Variant Y402H in Age- Related Macular 
Degeneration (AMD) Susceptibility  Gene CFH and Trea tment Response of AMD: A 
Meta -Anal ysis. PloS ONE 2012; 7: e42464
Gorin MB. Genetic insights into age -related macular degeneration: Controversies 
addressing risk, causality, and therapeutics. Mol. Asp. Med. 2012; 33: 467 -486.
2016N275054_04 CONFIDENTIA L
204959
8512.8. Appendix 8 -Country  Specific R equirements
No country -specific requirements exist.
2016N275054_04 CONFIDENTIA L
204959
8612.9. Appendix 9: Protocol Changes
12.9.1. Protocol A mendment 02
Scope:
This amendment applies to all sites.
Protocol Changes specified in Amendment No. 2 are summarised below.
Strike through text refers to deleted text and underlined refers to added text.
Section 1 Protocol Synopsis - Overall Design
Rationale for change: To explain why  each autoinjector will be labelled in one of tw o 
different formats .
Added Text:
Due to differences in the labelling requirements among regulatory  authorities around the 
world, two different labelling approaches will be included in this global study :  labelling 
that includes a pictogram plus standard labelling elements, or a standard labelling without 
the pictogram.  The pictogram plus sta ndard labelling elements is intended to satisfy  
requirements of the US Food and Drug Administration; while the standard labelling 
(without pictogram) is intended to satisfy  requirements of Regulatory  Agencies outside of 
the United States.  English speaking subjects outside of the US can contribute to the 
cohort used to assess the US label.  All subjects at a given clinical trial site will utilise the 
same format of device label for all injections throughout the study .  The assessment of 
injection success wi ll be reported separatel y according to the format of labelling used.
Section 1 Protocol Synopsis – Type and Number of Subjects
Rationale for change : To allow subjects who have a requirement for high dose ICS but 
who may  not have received continuous high 
dose ICS to be enrolled and increase subject 
numbers to account for the two different labelling formats.
Revised Text :
Male or female subjects aged 12 years or older with severe eosinophilic asthma. Subjects 
must either have been receiving mepolizumab admi nistered SC for the treatment of 
severe eosinophilic asthma every  4 weeks for at least 12 weeks prior to Visit 1 or, if not 
previously  using mepolizumab must be using , or have a requirement for ,high dose 
inhaled corticosteroids plus an additional controll er with a history  of 1 or more 
exacerbations requiring systemic corticosteroids in the 12 months prior to Visit 1.
Approximately  150 225subjects will be screened to achieve 105158enrolled subjects 
with the aim of achieving 100 150completed/evaluable su bjects. Approximately  100 
subjects will use autoinjectors with labelling that includes a pictogram plus standard 
labelling elements and 50 subjects will use the standard labelling without the pictogram.
2016N275054_04 CONFIDENTIA L
204959
87Section 1 Protocol Synopsis – Sample Size Calculation s and Statistical Analyses
Rationale for change: To increase the number of subjects to account for the two 
different label formats.
Revised Text:
No formal sample size calculations were performed. Assuming a 30% dropout screen 
failure rate during screening , approximately  150 225subjects will be screened in order to 
enrol 105 158subjects (attempting at least one self- administration of mepolizumab). 
Assuming a dropout rate of up to 5% during the study , 105 158enrolled subjects should 
provide at least 100 150subjects with complete study  data.
The number and percentage of subjects successfully  able to self -administer their doses 
will be reported presented separately  for the group of subjects using labelling that 
includes a pictogram plus standard labelling elements or the group using the standard 
labelling without the pictogram, together with including 95% confidence intervals.  No 
hypothesis testing will be performed.
Section 2.1 Study Rationale
Rationale for change: To indicate that the purpose of the study is to assess real world 
use of the autoinjector and hence the population is meant intended to broadly  
representative of subjects who may  use the autoinjector. 
Added Text:
Thus, th eprimary  objective of this study  is to characterise the degree of appropriate use 
of the autoinjector b y a group of subjects representative (i.e., similar age, dexterity  and 
cognitive abilities, degree of training or experience with an autoinjector) of pat ients, 
likely  to use the autoinjector as a self -injected medicine. A separate study  (Study  205667) 
will characterise the appropriate use of the safet y syringe.
Section 3 Objectives and Endpoints
Rationale for change: To remove incidence of asthma exacerbat ions as a safet y endpoint 
and reclassify  it as an ‘other’ endpoint as assessment as asthma exacerbations arenot 
considered a safety  endpoint. To remove ‘ Investigator ’from ‘Evaluation of user/device 
errors ’as this may  also be performed by  a designee.
2016N275054_04 CONFIDENTIA L
204959
88Revised Text:
Objectives Endpoints
Primary
To assess the use of the combination 
product, mepolizumab liquid drug 
product in autoinjector for the 
subcutaneous self -administration of 
mepolizumab by  subjects with severe 
eosinophilic asthmaProportion of subjects successfull y able 
to self -administer their observed third 
dose at Week 8
Secondary
To assess the use of mepolizumab 
liquid drug product in autoinjector 
outside the clinic settingProportion of subjects successfull y 
able to self -administer their 
unobserved second dose outside the 
clinic setting at Week 4
2016N275054_04 CONFIDENTIA L
204959
89Objectives Endpoints
Other
To assess the use of mepolizumab 
liquid drug product in autoinjector both 
inside and outside of the clinic setting
To evaluate autoinjector use & 
functionality
To evaluate an y autoinjector injection 
errors/failures related to use or device 
performance
To characterise the subject experience 
of using the mepolizumab liquid drug 
product in autoinjector
To assess mepolizumab plasma trough 
concentrations following the SC 
administration of mepolizumab liquid 
drug product in autoinjector
To assess the pharmacodynamic effect 
following the SC administration of 
mepolizumab liquid drug product in 
autoinjector
To assess the frequency  of asthma 
exacerbationsProportion of subjects successfull y able 
to self -administer their observed first 
dose at Week 0
Proportion of subjects successfull y able 
to self -administer both their unobserved 
second dose and observed third dose at 
Weeks 4 and 8
Proportion of subjects successfull y abl e 
to self -administer all three doses at 
Weeks 0, 4 and 8
Device usabilit y/functionality
questionnaire completed at the End of 
Study /Earl y Withdrawal Visit
Investigator Evaluation of user/device 
errors
Root cause anal ysis of each 
unsuccessful injection
Subject Exit I nterviews completed over 
the telephone after the End of 
Study /Earl y Withdrawal Visit
Mepolizumab plasma trough 
concentrations (Ctrough) at Weeks 4, 8 
and 12
Ratio to baseline of blood eosinophils 
at  Weeks 4, 8 and 12
Incidence of asthma exa cerbations
2016N275054_04 CONFIDENTIA L
204959
90Objectives Endpoints
Safety
To evaluate the safet y and tolerability  of 
mepolizumab liquid drug product in 
autoinjectorIncidence and frequency  of Adverse 
Events / Serious Adverse Events 
including s ystemic reactions and 
injection site reactions
Clinically  significant change in 
haematological and/or clinical 
chemistry  parameters
Incidence of asthma exacerbations
Vital signs
12-lead electrocardiogram (ECG)
Incidence of immunogenicity
Level of self -reported pain immediately  
following,1- and 24-hours following 
each injection (patient diary )
Section 4.1 Overall Study Design
Rationale for change: To indicate that two different formats will be used for the labels 
on the autoinjector depending on the country  in which it is to be used.
Added Text:
Each autoinjector will have labelling that includes a pictogram plus standard labelling 
elements, or a standard labelling without the pictogram dependant on the country  in 
which it is being used.
Rationale for change: To clarify  that a designee may  complete the Observer checklist.
Revised Text:
Observations about the injection will be recorded by  the investigator or designee for the 
doses administered in the clinic using an observer checklist.
All injections will be assessed by the investigator for su ccess based on:
Direct observation of the self- administration using the investigator Observer 
Checklist if the mepolizumab dose was administered in the clinic, and inspection 
of the autoinjector
2016N275054_04 CONFIDENTIA L
204959
91Subject/caregiver completed checklist and inspection by theinvestigator of the 
returned autoinjector if the mepolizumab dose was administered outside the clinic
A self -administered injection is considered successful if the following criteria are met: 
Use of a correct injection site (abdomen/thigh or upper arm [c aregiver onl y])
Full dose administration: subject pushes the autoinjector all the way  down and 
holds until either the second click, or the plunger stops moving and the inspection 
window is filled with the y ellow indicator or pushes the autoinjector all the way 
down and holds for a total of 15 seconds
No observations are made with respect to the autoinjector, following inspection 
by the investigator , which indicates the full dose has not been dispensed
If the above criteria are met, the investigator or designee will confirm the injection was 
successfull y delivered.
Rationale for cha nge: To amend text to indicate that a ll autoinjectors will need to be 
returned to GSK for inspection.
Revised text:
All devices associated with an unsuccessful injection, will be evaluated b y Device 
Engineering at GlaxoSmithKline (GSK), post-use, to assess overall performance and 
robustness of the device.
Section 4.3 Type and Number of Subjects
Rationale for change: To increase subject numbers to account for the two different 
labelling formats.
Revised Text:
Approximately  150 225subjects with severe eosinophilic asthma will be screened in 
order to achieve 105158enrolled subjects (attempting at least one self -administration of 
mepolizumab) and 100 150subjects with complete study  data. Approximately  100 
subjects will use autoinjectors with labelling that includes a pictogram plus standard 
labelling elements and 50 subjects will use the standard labelling without the pictogram.
Section 4.4 Design Justification
Rationale for change: To explain that the study is designed to assess the real world use 
of the autoinjector rather than the efficacy  of mepolizumab ,hence wh y subjects not on 
mepolizumab may  be enrolled based on a requirement for high dose I CS to prevent 
exacerbations if not receiving continuous high dose I CS.
2016N275054_04 CONFIDENTIA L
204959
92Revised Text:
An open -label, repeat -dose, single arm, multi -centre study  design is deemed appropriate 
to evaluate self -administration of mepolizumab liquid drug product in autoinjecto r in 
subjects with severe eosinophilic asthma. The primary  purpose, and resultant study  
design is to assess the appropriate use of the autoinjector in a real world use setting.  
Participants are intended to be broadl y representative of patients and caregiv ers (i.e., 
similar age, dexterity  and cognitive abilities, degree of training or experience with an 
autoinjector) who may  use the autoinjector, either for the treatment of severe eosinophilic 
asthma or, potentially , other approved indications. I n addition, safet y outcomes, 
immunogenicit y, pharmacokinetics and pharmacodynamics will be also be characteri sed 
in this study . 
A population of subjects with severe eosinophilic asthma either currentl y receiving or not 
currentl y receiving commerciall y available mepo lizumab SC at study  entry  (Visit 1) was 
selected to reflect the intended population in “real world” useconditions. Subjects not 
currentl y receiving mepolizumab will have a history of ≥1 exacerbation requiring 
treatment with sy stemic corticosteroids in the previous 12 months while will be required 
to have severe eosinophilic asthma and while using, or having a requirement for , high 
dose inhaled corticosteroids (I CS)plus a second controller .with a history  of ≥1 
exacerbations requiring treatment with systemic corticosteroids in the previous 12 
months . 
Rationale for change: To explain why  two different labelling formats for the 
autoinjector are being used.
Added Text:
Due to differences in the labelling requirements among regulatory  authorities around the 
world, two different labelling approaches will be included in this global study :  labelling 
that includes a pictogram plus standard labelling elements, or a standard labelling without 
the pictogram.  The pictogram plus standard labelling elements is in tended to satisfy  
requirements of the US Food and Drug Administration; while the standard labelling 
(without pictogram) is intended to satisfy  requirements of Regulatory  Agencies outside of 
the United States.  English speaking subjects outside of the US ca n contribute to the 
cohort used to assess the US label.  All subjects at a given clinical trial site will utilise the 
same format of device label for all injections throughout the study .  The assessment of 
injection success will be reported separatel y acco rding to the format of labelling used.
Rationale for change: To clarify  the wording around observation of the injection at Visit 
2
Amended Text:
The standardised training provided in this study will be representative of the instruction 
and training materia ls that will be given once the device is commercially available for 
use. Subjects will be observed self -administering liquid drug product from the 
autoinjector instructed to use the autoinjector at the clinic immediately  after being 
trained in its use at Visit 2 (Week 0). and thereafter Subjects will self -administer at 4-
2016N275054_04 CONFIDENTIA L
204959
93weekly intervals , either at the clinic or outside of the clinic (Time and Events Table, 
Section 7.1 ).
Section 4.6.2 Benefit Assessment
Revised Text:
The primary  purpose of this study  is to assess the appropriate use of the autoinjector in a 
real world use setting.  Participants are intended to be broadl y representative of patients 
and caregivers (i.e., similar age, dexterity  and cognitive abilities, degree of training or 
experience with an autoinjector) who may use the autoinjector, either for the treatment of 
severe eosinophilic asthma or, potentially , other approved indications. Efficacy  is not 
being assessed in this study   as the efficacy  of mepolizumab in severe eosinophilic 
asthma has previousl y been demonstrated in prior studies Data from earlier studies
[Haldar, 2009; Nair, 2009; Pavor d, 2012; ] attest to the clinical utility  of mepolizumab in 
the treatment of severe eosinophilic asthma which was confirmed in the Phase III studies 
MEA115575 and MEA115588[ Bel, 2014; Ortega, 2014].  The autoinjector is intended to
provide sa more convenie nt mode of delivery  from previous mepolizumab administration 
and potentially  provides gives patients an option to self -administer mepolizumab at 
home.
Section 5.1 Inclusion criterion 5
Rationale for change: To allow subjects who may  not have received conti nuous high 
dose I CS to beenrolled provided that it can be demonstrated that they  have need to for 
high dose ICS to prevent exacerbations or financial or tolerance issues have prevented 
them receiving continuous high dose ICS .
Revised text: 
5. Inhaled Corticosteroid: A well -documented requirement for regular treatment with 
high dose inhaled corticosteroid (ICS) in the 12 months prior to Visit 1 with or 
without maintenance oral corticosteroids (OCS).
For subjects  18 years old:
ICS dose must be ≥880 mcg/day  fluticasone propionate (FP) (ex-
actuator) or equivalent daily .
For ICS/long -acting -beta-2-agonist (LABA) combination 
preparations, the high strength approved maintenance dose in the local 
country  will meet this I CS criterion.
For subjects  12 to 17 years old:
ICS dose must be ≥440 mcg/day  FP (ex -actuator) or equivalent dail y.
For ICS/LABA combination preparations, the 
mid-strength approved 
maintenance dose in the local country  will meet this I CS criterion.
(Subjects will be permitted to be enrolled without continuous high dose ICS providing 
the subject was receiving continuous ICS and the Investigator attests that the subject 
2016N275054_04 CONFIDENTIA L
204959
94should have been treated with high dose ICS to mitigate the risk of exacerbations but 
financial or tolerance issues p revented the use of high- dose ICS. Such subjects should 
be discussed with GSK Medical Monitor prior to enrolment )
Section 5.3 Continuation to Treatment Criteria
Rationale for change: To reflect increase in subject numbers
Revised text:
At Visit 2, those subjects who continue to meet the inclusion/exclusion criteria and who 
meet the continuation to treatment criteria will commence the stud y treatment phase until 
the target of approximately  105 158enrolled subjects is reached.  
Section 6.2 Medical Devices
Rationale for change: To indicate that the labelling will differ depending on the 
geographical region in which the device is to be used.
Revised text:
The devices used in the study  are representative of the devices and regionally  appropriate 
device product labelling planned to be marketed for the product.
Section 6.5 Packaging and Labelling
Rationale for change: To describe the two different formats that will be used to label the 
autoinjector.
Added text:
The autoinjector will either be labelled with a pict ogram plus standard labelling elements 
or standard labelling without the pictogram.
Section 6.7 Training Session
Rationale for change: To remove reference to a practice injection by  injecting into a 
foam pad. 
Revised text:
The subject/caregiver will then perform a supervised practice injection using a 
demonstration device and injecting into a foam pad.  Finall y,The first actual injection 
will then be supervised observed by site personnel and may  include feedback to the 
subject as needed.
Section 6.8.1 Self- Administration at the Clinic
Rationale for change: To clarify  that a designee may  complete the O bserv erchecklist
2016N275054_04 CONFIDENTIA L
204959
95Revised Text:
Observations about the injection will be recorded by  the investigator or designee using a 
checklist for the doses administered in the clinic.
Section 6.11.1 Permitted Medications and Non -Drug Therapies
Rationale for change: To allow subjects who may  not have received continuous high 
dose I CS to be enrolled provided that it can be demonstrated that they  have need for high 
dose I CS to prevent exacerbations but financial or tolerance issues have prevented them 
receiving continuous high dose I CS.
Revised text:
For subjects who have not previously received mepolizumab, subjects must have a 
well-documented requirement for regular treatment with high dose inhaled corticosteroid 
(ICS) in the 12 months prior to Visit 1 with or without maintenance oral corticosteroids 
(OCS).
Subjects  18 years old:
ICS dose must be ≥880 mcg/day  fluticasone propion ate (FP) (ex -
actuator) or equivalent daily .
For ICS/LABA combination preparations, the highest strength 
approved maintenance dose in the local country  will meet this I CS 
criterion.
Subjects  12 to 17 years old:
ICS dose must be ≥440 mcg/day  FP (ex-actuator) or equivalent dail y.
For ICS/LABA combination preparations, the 
mid-strength approved 
maintenance dose in the local country  will meet this I CS criterion.
(Subjects will be permitted to be enrolled without continuous high dose ICS providing 
the subject was receiving continuous ICS and the Investigator attests that the subject 
should have been treated with high dose ICS to mitigate the risk of exacerbations but 
financial or tolerance issues prevented the use of high-dose ICS. Such subjects should 
be discussed with GSK Medical Monitor prior to enrolment )
Section 7.1 Time and Events Table
Rationale for change : Asthma exacerbations previously  omitted as an assessment during 
the study :
Added text:
Physical/Clinical:
Vital signsi X Xd Xd Xd X
12-lead ECG X X
Physical examination X X
Weight X
2016N275054_04 CONFIDENTIA L
204959
96Physical/Clinical:
Concomitant Medication X X X X X X
Asthma Exacerbations X X X X X
Serious Adverse Eventsj,k,l X X X X X X
Adverse Eventsj,k,l X X X X
Section 7.3 Assessment of Autoinjector Use
Rationale for change: To indicate that a designee may  inspect the device after each 
injection.
Revised Text:
In addition, the investigator or designee will be asked to inspect the autoinjector, 
following each injection, to confirm that the yellow indicator fills the inspection window 
and the needle guard has locked into place (checked by  pressing the needle guard against 
a firm surface), as well as noting an y additional observations which indicate the full dose 
has not been dispensed.
Rationale for change: To amend text to indicate that all autoinjectors will need to be 
returned to GSK for inspection.
Revised text:
All devices associated with an unsuccessful injection , will be evaluated b y Device 
Engineering, post -use, to assess overall performance and robus tness of the device.
Section 7.8 Asthma Exacerbations
Rationale for change: Definition of asthma exacerbation omitted previously including
details of how exacerbations should be recorded.
Added Text:
At each stud y visit the investigator will make an assess ment of the occurrence of an 
asthma exacerbation.  Any asthma exacerbation will be recorded on the appropriate eCRF 
page.
An exacerbation of asthma as defined as:
Worsening of asthma which requires use of s ystemic corticosteroids1and/or 
hospitalization and /or Emergency Department (ED) visits.
1For all subjects, i.v. or oral steroid (e.g., prednisone) for at least 3 days or a single 
intramuscular corticoster oiddose is required. For subjects on maintenance systemic 
corticosteroids, at least double the existing maintenance dose for at least 3 days is 
required.
2016N275054_04 CONFIDENTIA L
204959
97Section 9.1 Hypotheses
Rationale for change :To amend the text to indicate that the results will be rep orted 
separately  for the two different formats being used for the labels
Revised text :
No formal statistical h ypothesis testing is planned.  The number and percentage of 
subjects successfull y able to self -administer their mepolizumab dose will be reported
presented No formal statistical hy pothesis testing is planned.  The number and percentage 
of subjects successfully  able to self -administer their mepolizumab dose will be reported 
separately  for the group of subjects using labelling that includes a pictogra m plus 
standard labelling elements or the group using the standard labelling without the 
pictogram, including 95% confidence intervals (CI ). No comparison between the labels 
will be performed.
Section 9.2.1 Sample Size Assumptions
Rationale for change : To increase the number of subjects to account for the two 
different label formats.
Revised text:
No formal sample size calculations were performed. Assuming a 30% dropout screen 
failure rate during screening , approximately  150 225subjects will be screened in order to 
enrol 105 158subjects (attempting at least one self- administration of mepolizumab). 
Assuming a dropout rate of up to 5% during the study , 105 158enrolled subjects should 
provide at least 100150subjects with comple te study  data. Approximately  100 subjects 
will use autoinjectors with labelling that includes a pictogram plus standard labelling 
elements and 50 subjects will use the standard labelling without the pictogram.
Section 9.2.2 Sample Size Sensitivity
Rational e for change : To amend the table to include the estimated precision both for the 
100 subjects and 50 subjects according to the label used. 
Revised text:
The estimated precision for the proportion of subjects successfull y able to self -administer 
their mepo lizumab dose is presented below. assuming 100 completed subjects Sample 
sizes of both 100 and 50 completed subjects are included, corresponding to the number of 
subjects planned to use the autoinjectors with labelling that includes a pictogram plus 
standar d labelling elements and the standard labelling without the pictogram 
respectivel y:-
2016N275054_04 CONFIDENTIA L
204959
9895% CI
(Exact Method)
Observed Proportion
(%)N=100 N=50
70 60, 79 55, 82
80 71, 87 66, 90
82 73, 89 69, 91
84 75, 91 71, 93
86 78, 92 73, 94
88 80, 94 76, 95
90 82, 95 78, 97
92 85, 96 81, 98
94 87, 98 83, 99
96 90, 99 86, 100
98 93, 100 89, 100
Section 9.4.1 Analyses to Evaluate Autoinjector
Rationale for change: To indicate that the results will be reported separately  according 
to the format of the label being used.
Added text:
All analy ses to evaluate the autoinjector will be reported separatel y for subjects using 
autoinjectors with labelling that includes a pic togram plus standard labelling elements or 
subjects using the standard labelling without the pictogram.
2016N275054_04 CONFIDENTIA L
204959
9912.9.2. Protocol A mendment 01
Scope:
This amendment applies to all sites.
Protocol Changes specified in Amendment No.1 are summarised below.
Strike through text refers to deleted text and underlined refers to added text.
Protocol Changes
Section 1 Protocol Synopsis -Objective(s)/Endpoints
Rationale for change: To present the primary  endpoint in a tabular format and include 
the secondary  endpoint, as per GSK protocol template standard.
Revised text:
The primary  endpoint is the proportion of subjects successfull y able to self -administer 
their observed third dose using the safet y syringe at the clinic at Week 8.
The primary  and secondary  objectives and associated endpoints are outlined below:
Objectives Endpoints
Primary
To assess the use of the combination 
product, mepolizumab liquid drug 
product in autoinjector for the 
subcutaneous self -administration of 
mepolizumab by  subjects with severe 
eosinophilic asthmaProportion of subjects successfull y able 
to self -administer their observed third 
dose at Week 8
Secondary
To assess the use of mepolizumab 
liquid drug product in autoinjector 
outside the clinic settingProportion of subjects successfull y 
able to self-administer their 
unobserved second dose outside the 
clinic setting at Week 4
Section 4.1 Overall Design 
Rationale for change: To refine the criteria for a successful injection following a use -
related risk review
2016N275054_04 CONFIDENTIA L
204959
100Revised text: 
Autoinjector positio ned with the y ellow needle guard flat on the skin and pushed 
all the way  down until a full dose is administered (for a full dose to be 
administered, the subject must either wait for the second click, the plunger to stop 
moving, the inspection window to be filled with the y ellow indicator or hold the 
autoinjector down for a total of 15 seconds)
Full dose administration: subject pushes the autoinjector all the way  down and 
holds until either the second click, or the plunger stops moving and the inspection 
window is filled with the yellow indicator or pushes the autoinjector all the way  
down and holds for a total of 15 seconds
Section 5.1 Inclusion Criterion No. 9/ Exclusion Criterion No. 15
Rationale for change : Included additional text to I nclusion Criterion 9 to allow 
Exclusion Criterion 15 to be removed:
Revised text:
9.Gender: Male or Female
Females : 
A female subject is eligible to participate if she is not pregnant (as confirmed by  a 
negative urine human chorionic gonadotrophin (hCG) test), planning to bec ome pregnant 
during the time of stud y participation (and up to 16 weeks after the last dose ), not 
lactating, and at least one of the following conditions applies:
15.  Pregnancy: Subjects who are pregnant or breastfeeding. Patients should not be 
enrolled i f they  plan to become pregnant during the time of study participation (and up to 
16 weeks after the last dose).
Section 5.1 Exclusion Criterion No. 7
Rationale for change: To allow Bazett’s to be used as the correction formula for heart 
rate when measuring the QT interval consistent with text elsewhere in the protocol.
Revised Text:
7.  ECG Assessment: QT interval corrected for heart rate by  either Fridericia’s or 
Bazett’s formula QTc(F)/ QTc(B) ≥450msec or QTc(F)/ QTc(B) ≥480 msec for subjects 
with Bundle Branch Block at Visit 1.
Section 7.3 Assessment of Autoinjector Use
Rational for change: To refine the criteria for a successful injection following a use -
related risk revie w
2016N275054_04 CONFIDENTIA L
204959
101Revised text:
At Visit 2 (Week 0), and at Visit 4 (Week 8), the investigator or designee will observe, 
using a checklist based on the autoinjector IFU, the ability  of the subject/caregiver to 
(self) -administer the injection. The Observer Checklist (see SRM) will be used to 
determine if each step, according to the IFU, was completed easily , with some difficulty  
or not completed /intervention required .
Failure to perform one of the critical steps, i.e., correct choice of injection site , 
autoinjector position ed with the y ellow needle guard flat on the skin and pushed all the 
way down until and a full dose is administered (for a full dose to be administered,
determined b ythe subject must pushing the autoinjector all the way down and holding 
until either wait f orthe second click ,orthe plunger to stopsmoving ,and the inspection 
window to be is filled with the yellow indicator or hold bythe autoinjector being pushed 
all the way  down and held for a total of 15 seconds) will be deemed to be a failure to 
success fully administer the injection.
Section 10.7 Provision of Study Results to Investigators
Rationale for change: Delete text related to randomization codes as study  is open- label 
and randomization codes will not be used.
Revised text: 
GSK will provide the i nvestigator with the randomization codes for their site only  after 
completion of the full statistical analy sis.
Section 11 References
Rationale for change : References not cited in the document.
Revised text:
Hatcher RA, Trussell J, Nelson AL, Cates W Jr, S tewart F, Kowal D, editors. 
Contraceptive Technology . 19thedition. New York: Ardent Media, 2007(a): 24. Table 3 -
2.
Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Stewart F, Kowal D, editors. 
Contraceptive Technology . 19thedition. New York: Ardent Media, 2007(b): 28.
Section 12.3.4 Appendix 3 
Rationale for change: References not cited in document
Revised text:
CHMP, 2005 -EMA -Guideline on Adjuvants in Vaccines for Human Use, 
(CHMP/VEG/134716/2004), January  2005.
2016N275054_04 CONFIDENTIA L
204959
102Cole LA, Khanlian SA, Sutton JM, Davies S, Rayburn WF. Accuracy of home pregnancy  
tests at the time of missed menses. Am J Ob Gy n 2004(190):100 -5.
EMA/CHMP/I CH/449035/2009: General principles to address virus and vector shedding. 
http://www.ema.europa.eu/docs/e n_GB/document_library /Scientific_guideline/2009/09/
WC500002680.pdf Accessed 28 Nov 2014.
EMEA/CHMP/GTWP/125459/2006: Guideline on the Nonclinical Studies Required 
Before First Clinical Use of Gene Therap y Medicinal Products [2008]
FDA CBER Guidance for in dustry , “Considerations for Developmental Toxicity  Studies 
for Preventive and Therapeutic Vaccines for Infectious Disease Indications. U.S. FDA; 
Feb. 2006. 
FDA Medical Devices Safet y Alerts and Notices, “Blood human chorionic gonadotropin 
(hCG) assay s:What laboratorians should know about false -positive results”, 
http://www.fda.gov/MedicalDevices/Safet y/AlertsandNotices/TipsandArticlesonDeviceS
afety/ucm109390.htm, accessed 17 Nov 2014.
International Conference on Harmonization of Technical Requirements fo r Registration 
of Pharmaceuticals For Human Use. ICH Harmonized Tripartite Guideline. Detection of 
Toxicity  to Reproduction for Medicinal Products & Toxicity  to Male Fertility .Parent 
Guideline dated 24 June 1993 (Addendum dated 9 November 2000 incorpor ated in 
November 2005. ICH S5 (R2)
International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals For Human Use.   ICH Harmonized Tripartite Guideline. Nonclinical 
Evaluation for Anticancer Pharmaceuticals. ICH S9.2009.
International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals For Human Use. ICH Harmonized Tripartite Guideline. Nonclinical 
Safety  Studies for the Conduct of Human Clinical Trials and Marketing Author ization for 
Pharmaceuticals. ICH M3 (R2). 2009.
International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals For Human Use. ICH Harmonized Tripartite Guideline. Preclinical 
Safety  Evaluation of Biotechnology -Derived Pharmaceuticals. ICH S6 and Addendum 
ICH S6 (R1). 2011.
U.S. Dept of Health and Human Services, FDA, Center For Biologics Evaluation and 
Research: Guidance for Human Somatic Cell Therap y and Gene Therap y [1998]
WHO, 2013 -WHO -Guidelines on the Non clinical Evaluation of Vaccine Adjuvants 
and Adjuvanted Vaccines, 2013
World Health Organization. WHO/CONRAD Technical Consultation on Nonox ynol-9.
World Health Organization; Department of Reproductive Health and Research; Geneva; 
9-10 October 2001. Summary  Report. 2001. WHO/RHR/03.8.